

a. Is this an original filing? ...... Yes [X] No [ ]

b. If no,
1. State the amendment number.....
2. Date filed ......
3. Number of pages attached ......

# **HEALTH ANNUAL STATEMENT**

AS OF DECEMBER 31, 2022 OF THE CONDITION AND AFFAIRS OF THE

# Aetna Health of Michigan Inc.

NAIC Group Code

White Gloup o	(Current) (Price	or)	ode <u>93730</u> Emp	ployer's 1D Number	23-2601363					
Organized under the Laws of	Michigar	1	State of Domicile or P	ort of Entry	Mi					
Country of Domicile		United State	s of America							
Licensed as business type:		Health Maintena	nce Organization							
Is HMO Federally Qualified? Yes [ ]	No [X]									
Incorporated/Organized	09/10/1996		Commenced Busin	ness	04/01/1998					
-		Pu Suito 100	Commoniced Eddin							
Statutory Frome Office	588 Northwestern Highwa (Street and Number)	<del></del>			, MI, US 48034 e, Country and Zip Code)					
Main Administrative Office		28588 Northwestem	Highway, Suite 100							
Southfie	id, MI, US 48034	(Street and	d Number)	248-	-357-7766					
	ate, Country and Zip Code	9)			Telephone Number)					
	1 Farmington Avenue, RT				CT, US 06156					
(Str	reet and Number or P.O. E	Зох)		(City or Town, State	e, Country and Zip Code)					
Primary Location of Books and Records		28588 Northwesterr (Street and	Highway, Suite 100							
	ld, MI, US 48034				357-7766					
	ate, Country and Zip Code			(Area Code) (1	Telephone Number)					
Internet Website Address		www.ae	tna.com							
Statutory Statement Contact	Kim E. (Nar				215-775-6508					
StatutoryRe	eporting@aetna.com			•	de) (Telephone Number) 262-7767					
(E-r	mail Address)		(FAX Number)							
		OFFIC								
Vice President and Treasu Vice President and Secreta			rincipal Financial Office	er and Controller _	Steven Matthew Conte #					
		OTH	IFR							
Derek Scott Blunt, Senior Inve		Peter Keller, A	ssistant Controller		gory Stephen Martino, Vice President					
Whitney Dorothy Lavoie, Assis Mark Alan Stiglitz, Pres		Cara Sue Mullen	Assistant Controller	Bradley /	Leland Spradin, Senior Medical Director Andrew Thompson, Assistant Controller #					
		DIRECTORS O	R TRUSTEES							
Suzanne Marie Hai Scott Leland Spradli					Paul Martin Messimer Mark Alan Stiglitz #					
			al and the state of		and that on the reporting period stated above					
all of the herein described assets were statement, together with related exhibits condition and affairs of the said reporting in accordance with the NAIC Annual Sta rules or regulations require differences in Furthermore, the scope of this attestation	the absolute property of it, schedules and explanation gentity as of the reporting atterment Instructions and A in reporting not related to acomply the described office	the said reporting entity, ons therein contained, ar period stated above, and Accounting Practices and ccounting practices and I ars also includes the rela	free and clear from an nnexed or referred to, is d of its income and dedi d Procedures manual e procedures, according to ted corresponding elec	ny liens or claims the a full and true state uctions therefrom for except to the extent to to the best of their inforty ctronic filing with the	tereon, except as herein stated, and that the ment of all the assets and liabilities and of the rithe period ended, and have been complete that: (1) state law may differ; or, (2) that state formation, knowledge and belief, respectively a NAIC, when required, that is an exact copious regulators in lieu of or in addition to the					
Tragy Louise Smith	<u> </u>	Edward Ch			Steven Matthew Conte					
Vice President and Treasure	∍r	Vice President	and Secretary	Р	rincipal Financial Officer and Controller					
State of Rhode Island County of Providence		ite of Connecticut unty of Hartford			f Pennsylvania of Montgomery					
Subscribed and sworn to before me this	Sul	bscribed and sworn to be	efore me this	Subscri	ibed and sworn to before me this					
ols day of January		day of	, 202	23 10th	day of February , 2023					
of Ihand	$\supset$				1-					
NOTARY PUBLIC (Seal)		TARY PUBLIC (Seal)			NY PHIPLIO (Ozell)					
TOTALLI (Seal)	140	TART FUBLIC (Seal)		NOTAR	RY PUBLIC (Seal)					
SUSAN J. GEORGE  NOTARI PUBLIC  STATE OF RISONE ISL. IND  COMMISSION F 74967  COMMISSION EXPIRES 812612023				му Со	wealth of Pennsylvania - Notary Seal KIM E. ROTH, Notary Public Montgomery County ommission Expires April 25, 2025 Commission Number 1141410					



# **HEALTH ANNUAL STATEMENT**

AS OF DECEMBER 31, 2022 OF THE CONDITION AND AFFAIRS OF THE

# Aetna Health of Michigan Inc.

NAIC Group (	Code 0001 0001 NAIC Compa (Current) (Prior)	any Code <u>95756</u> Employer's ID N	lumber23-2861565
Organized under the Laws of		State of Domicile or Port of Entry	MI
Country of Domicile	United	States of America	
Organized under the Laws of Michigan State of Domicile or Port of E  Country of Domicile United States of America  Licensed as business type: Health Maintenance Organization  Is HMO Federally Qualified? Yes [ ] No [ X ]  Incorporated/Organized 09/10/1996 Commenced Business  Statutory Home Office 28588 Northwestern Highway, Suite 100 (Street and Number) (City of Southfield, MI, US 48034  (City or Town, State, Country and Zip Code) (American Number)  Mail Address 151 Farmington Avenue, RT21 (Street and Number or P.O. Box) (City of Southfield, MI, US 48034  Primary Location of Books and Records 28588 Northwestern Highway, Suite 100 (Street and Number) (City of Southfield, MI, US 48034		tenance Organization	
Is HMO Federally Qualified? Yes [ ]	] No[X]		
Incorporated/Organized	09/10/1996	Commenced Business	04/01/1998
		<del></del>	outhfield, MI, US 48034
			vn, State, Country and Zip Code)
Main Administrative Office			
Southfie		et and Number)	248-357-7766
		(Area	Code) (Telephone Number)
Mail Address1	51 Farmington Avenue, RT21	Ha	artford, CT, US 06156
(St			vn, State, Country and Zip Code)
Primary Location of Books and Record			
Southfie	•	et and Number)	248-357-7766
		(Area	Code) (Telephone Number)
Internet Website Address	ww	w.aetna.com	
Statutory Statement Contact	Kim E. Roth		215-775-6508
			Area Code) (Telephone Number)
		<del></del>	860-262-7767 (FAX Number)
Derek Scott Blunt, Senior Inv Whitney Dorothy Lavoie, Assi Mark Alan Stiglitz, Pre  Suzanne Marie Ha Scott Leland Spradl  The officers of this reporting entity being all of the herein described assets were statement, together with related exhibits condition and affairs of the said reportin n accordance with the NAIC Annual Strules or regulations require differences i Furthermore, the scope of this attestatic except for formatting differences due to	estment Officer  istant Controller  esident #  DIRECTOF  all  g duly sworn, each depose and say that they a be the absolute property of the said reporting e be s, schedules and explanations therein containe g entity as of the reporting period stated above atternent Instructions and Accounting Practice n reporting not related to accounting practices ion by the described officers also includes the	er, Assistant Controller  ullen, Assistant Controller  RS OR TRUSTEES  re the described officers of said reporting entity, free and clear from any liens or cled, annexed or referred to, is a full and tre, and of its income and deductions there is and Procedures manual except to the and procedures, according to the best of the related corresponding electronic filing are related corresponding electronic filing.	laims thereon, except as herein stated, and that this ue statement of all the assets and liabilities and of the efrom for the period ended, and have been completed extent that: (1) state law may differ; or, (2) that state their information, knowledge and belief, respectively with the NAIC. when required, that is an exact copy
			Steven Matthew Conte Principal Financial Officer and Controller
State of Rhode Island County of Providence	State of Connecti County of Hartford		State of Pennsylvania County of Montgomery
Subscribed and sworn to before me this			Subscribed and sworn to before me this
day of	, 2023	DALOUS, 2023 JULIO UNU	day of <u>February</u> , 2023
NOTARY PUBLIC (Seal)	NOTARY PUBLIC (Se	ZENDYANN CIANCI ary Public, State of Connecticut pumission Expires Nov. 20, 2025	NOTARY PUBLIC (Seal)

3. Number of pages attached......

# **ASSETS**

			Current Year	_	Prior Year
		1 Assets	2 Nonadmitted Assets	3 Net Admitted Assets (Cols. 1 - 2)	4 Net Admitted Assets
1.	Bonds (Schedule D)	18,723,051	0	18,723,051	2,005,807
2.	Stocks (Schedule D):				
	2.1 Preferred stocks		0	0	
	2.2 Common stocks	1,166,217	0	1,166,217	
3.	Mortgage loans on real estate (Schedule B):				
	3.1 First liens	0	0	0	
	3.2 Other than first liens			0	
4.	Real estate (Schedule A):				
	4.1 Properties occupied by the company (less \$				
	encumbrances)	0	0	0	
	4.2 Properties held for the production of income (less				
	\$ encumbrances)			0	
	4.3 Properties held for sale (less \$				
	encumbrances)			0	
5.	Cash (\$1,236,611 , Schedule E - Part 1), cash equivalents				
	(\$95,282,506 , Schedule E - Part 2) and short-term				
	investments (\$, Schedule DA)	96,519,117		96,519,117	26,070,055
6.	Contract loans, (including \$ premium notes)	0	0	0	
7.	Derivatives (Schedule DB)		0	0	
8.	Other invested assets (Schedule BA)			0	
9.	Receivables for securities				
10.	Securities lending reinvested collateral assets (Schedule DL)		0	0	
11.	Aggregate write-ins for invested assets	0	0	0	0
12.	Subtotals, cash and invested assets (Lines 1 to 11)	116,408,385	0	116,408,385	28,075,862
13.	Title plants less \$ charged off (for Title insurers				
	only)	0	0	0	
14.	Investment income due and accrued	143,043	0	143,043	4,924
	Premiums and considerations:				
	15.1 Uncollected premiums and agents' balances in the course of collection	235,448	169,390	66,058	49,680
	15.2 Deferred premiums, agents' balances and installments booked but				
	deferred and not yet due (including \$				
	earned but unbilled premiums)			0	
	15.3 Accrued retrospective premiums (\$0 ) and				
	contracts subject to redetermination (\$8,934,852 )	8,934,852	0	8,934,852	2,807,662
16.	Reinsurance:				
	16.1 Amounts recoverable from reinsurers				
	16.2 Funds held by or deposited with reinsured companies				
	16.3 Other amounts receivable under reinsurance contracts				
	Amounts receivable relating to uninsured plans				
	Current federal and foreign income tax recoverable and interest thereon $\dots$				
	Net deferred tax asset				
	Guaranty funds receivable or on deposit				
20.	Electronic data processing equipment and software	0	0	0	
21.	Furniture and equipment, including health care delivery assets				
	(\$)				
	Net adjustment in assets and liabilities due to foreign exchange rates				
	Receivables from parent, subsidiaries and affiliates				
	Health care (\$				
	Aggregate write-ins for other than invested assets	57,615	0	57,615	158,530
26.	Total assets excluding Separate Accounts, Segregated Accounts and Protected Cell Accounts (Lines 12 to 25)	134 . 476 . 443	357 .544	134 . 118 . 899	43.856.118
27.	From Separate Accounts, Segregated Accounts and Protected Cell				
28.	Accounts	134,476,443	357,544		43,856,118
	DETAILS OF WRITE-INS	101,112,112		,,	10,202,112
1101.	0	0	0	0	0
1101.	0				
1102.	0				
	Summary of remaining write-ins for Line 11 from overflow page				
	Totals (Lines 1101 thru 1103 plus 1198)(Line 11 above) State income tax receivable			•	_
		· ·		·	· ·
	0				
	0				
2599.	Totals (Lines 2501 thru 2503 plus 2598)(Line 25 above)	57,615	0	57,615	158,530

# **LIABILITIES, CAPITAL AND SURPLUS**

	LIABILITIES, CAP		Current Year		Prior Year
		1	2	3	4
		Covered	Uncovered	Total	Total
1.	Claims unpaid (less \$	•			
2.	Accrued medical incentive pool and bonus amounts				
3.	Unpaid claims adjustment expenses				
4.	Aggregate health policy reserves, including the liability of	700,004		700,004	200, 100
٦.	\$0 for medical loss ratio rebate per the Public				
	Health Service Act	0 117 761		0 117 761	649 447
5.	Aggregate life policy reserves	· · ·			
6.	Property/casualty unearned premium reserves				
7.	Aggregate health claim reserves				
7. 8.	Premiums received in advance				
9.	General expenses due or accrued				
	Current federal and foreign income tax payable and interest thereon				
10.1	(including \$ on realized capital gains (losses))	0		0	0
10.2	Net deferred tax liability				
11.	Ceded reinsurance premiums payable				
12.	Amounts withheld or retained for the account of others	0			
13.	Remittances and items not allocated				
14.	Borrowed money (including \$ current) and				
17.	interest thereon \$(including				
	\$current)	0		0	
15.	Amounts due to parent, subsidiaries and affiliates				
16.	Derivatives				
17.	Payable for securities.				
18.	Payable for securities lending				
19.	Funds held under reinsurance treaties (with \$				
	authorized reinsurers, \$				
	reinsurers and \$	1.859.000		1.859.000	296.450
20.	Reinsurance in unauthorized and certified (\$				200, 100
	companies	0		0	
21.	Net adjustments in assets and liabilities due to foreign exchange rates				
22.	Liability for amounts held under uninsured plans				
23.	Aggregate write-ins for other liabilities (including \$				, · · · ·
	current)	0	0	0	0
24.	Total liabilities (Lines 1 to 23)				
25.	Aggregate write-ins for special surplus funds				0
26.	Common capital stock				10
27.	Preferred capital stock				
28.	Gross paid in and contributed surplus				28,399,990
29.	Surplus notes				
30.	Aggregate write-ins for other than special surplus funds				
31.	Unassigned funds (surplus)				
32.	Less treasury stock, at cost:				
	32.1 shares common (value included in Line 26				
	\$	xxx	xxx	0	
	32.2 shares preferred (value included in Line 27				
	\$	xxx	xxx		
33.	Total capital and surplus (Lines 25 to 31 minus Line 32)				
34.	Total liabilities, capital and surplus (Lines 24 and 33)	XXX	XXX	134,118,899	43,856,118
	DETAILS OF WRITE-INS				
2301.	0	0	0	0	0
2302.	0	0	0	0	0
2303.	0	0	0	0	0
2398.	Summary of remaining write-ins for Line 23 from overflow page	0	0	0	0
2399.	Totals (Lines 2301 thru 2303 plus 2398)(Line 23 above)	0	0	0	0
2501.	0	XXX	XXX	0	0
2502.	0	xxx	xxx	0	0
2503.					0
2598.					0
2599.	Totals (Lines 2501 thru 2503 plus 2598)(Line 25 above)	XXX	XXX	0	0
	0	XXX		0	0
	0				0
	0				0
3098.					
~~~.		XXX	XXX	0	0

# **STATEMENT OF REVENUE AND EXPENSES**

	STATEMENT OF REVENUE AN			Drior Voor
		Current Y	ear2	Prior Year 3
		Uncovered	Total	Total
1. M	Member Months	XXX	349,573	123,346
	et premium income ( including \$ non-health premium income)			
3. Ch	hange in unearned premium reserves and reserve for rate credits	XXX	246,986	1,217,681
4. Fe	ee-for-service (net of \$ medical expenses)	xxx	0	
5. Ri:	isk revenue	XXX	0	
6. Ag	ggregate write-ins for other health care related revenues	xxx	0	0
	ggregate write-ins for other non-health revenues			0
	otal revenues (Lines 2 to 7)			
	ospital and Medical:			, -,
	ospital/medical benefits	19,629,765	259,759,105	
10. Ot	ther professional services	1,258,902	16,658,953	5 , 180 , 052
	utside referrals			
	mergency room and out-of-area		, , ,	5,869,302
				, ,
	rescription drugs			10,880,125
_	ggregate write-ins for other hospital and medical			
	centive pool, withhold adjustments and bonus amounts			
16. St	ubtotal (Lines 9 to 15)	31,438,417	351,685,207	116,814,156
-	ess:			
	et reinsurance recoveries			
18. To	otal hospital and medical (Lines 16 minus 17)	31,438,417	342,460,302	113,773,299
19. No	on-health claims (net)			
20. Cl	laims adjustment expenses, including \$		7,832,640	2,387,991
21. Ge	eneral administrative expenses		41,036,215	12,260,317
22. Inc	crease in reserves for life and accident and health contracts (including \$			
	increase in reserves for life only)	0	6,533,095	
23. To	otal underwriting deductions (Lines 18 through 22)	31,438,417	397,862,252	128,421,607
	et underwriting gain or (loss) (Lines 8 minus 23)			
	et investment income earned (Exhibit of Net Investment Income, Line 17)			
	et investment income earned (Exhibit of Net investment income, Line 17)			
	et investment gains (losses) less capital gains tax of \$\text{g}\$		1,648,582	
			1,040,302	31,990
	et gain or (loss) from agents' or premium balances charged off [(amount recovered		_	
	\$		0	
29. Ag	ggregate write-ins for other income or expenses	0	0	0
30. Ne	et income or (loss) after capital gains tax and before all other federal income taxes (Lines 24 plus 27 plus 28 plus 29)	VVV	3 380 802	(1.706.332
	ederal and foreign income taxes incurred			
	et income (loss) (Lines 30 minus 31)	XXX	1,770,344	(1,210,424
	ETAILS OF WRITE-INS		_	_
				0
				0
				0
	ummary of remaining write-ins for Line 6 from overflow page			0
	otals (Lines 0601 thru 0603 plus 0698)(Line 6 above)	XXX	0	0
				0
				0
				0
	ummary of remaining write-ins for Line 7 from overflow page			0
	otals (Lines 0701 thru 0703 plus 0798)(Line 7 above)	XXX	0	0
-				0
				0
			0	0
1498. Su	ummary of remaining write-ins for Line 14 from overflow page	0	0	0
	otals (Lines 1401 thru 1403 plus 1498)(Line 14 above)	0	0	0
			0	0
			0	0
				0
2998. St	ummary of remaining write-ins for Line 29 from overflow page	0	0	0
2999. To	otals (Lines 2901 thru 2903 plus 2998)(Line 29 above)	0	0	0

**STATEMENT OF REVENUE AND EXPENSES (Continued)** 

Current Year	2 Prior Year
21,080,350	12,307,314
1,770,344	(1,210,424)
0	
0	
0	
20,000,000	10,000,000
0	
0	0
22,917,979	8,773,036
43,998,329	21,080,350
0	0
0	0
0	0
0	0
0	0

# **CASH FLOW**

	CASITILOW	1	2
		Current Year	Prior Year
	Cash from Operations	Current real	FIIOI Teal
1.	Premiums collected net of reinsurance	395 286 694	123,320,663
2.	Net investment income		59,794
3.	Miscellaneous income	_	
4.	Total (Lines 1 through 3)		123,380,457
5.	Benefit and loss related payments		
6.	Net transfers to Separate Accounts, Segregated Accounts and Protected Cell Accounts		
7.	Commissions, expenses paid and aggregate write-ins for deductions		
8.	Dividends paid to policyholders		
9.	Federal and foreign income taxes paid (recovered) net of \$ tax on capital gains (losses)		942,445
10.	Total (Lines 5 through 9)		116, 157, 623
11.	Net cash from operations (Line 4 minus Line 10)		7,222,834
• • • •	Tide data non operations (Enter Filmido Ente Fo)	11,000,000	7,222,001
	Cash from Investments		
12.	Proceeds from investments sold, matured or repaid:		
12.	12.1 Bonds	0	2 075 000
	12.2 Stocks		
	12.3 Mortgage loans		
	12.4 Real estate		
	12.5 Other invested assets		
	12.6 Net gains or (losses) on cash, cash equivalents and short-term investments		(7
	12.7 Miscellaneous proceeds		
	12.8 Total investment proceeds (Lines 12.1 to 12.7)		2 074 993
13.	Cost of investments acquired (long-term only):	0,900,292	2,074,990
13.	13.1 Bonds	16 692 146	2 024 926
	13.2 Stocks		2,024,030
	13.3 Mortgage loans	, ,	
	13.4 Real estate		
	13.5 Other invested assets		
	13.6 Miscellaneous applications		0.004.000
	13.7 Total investments acquired (Lines 13.1 to 13.6)		2,024,836
14.	Net increase (decrease) in contract loans and premium notes		50.457
15.	Net cash from investments (Line 12.8 minus Line 13.7 minus Line 14)	(13,936,876)	50,157
4.0	Cash from Financing and Miscellaneous Sources		
16.	Cash provided (applied):		
	16.1 Surplus notes, capital notes		
	16.2 Capital and paid in surplus, less treasury stock		0
	16.3 Borrowed funds		
	16.4 Net deposits on deposit-type contracts and other insurance liabilities		
	16.5 Dividends to stockholders	0	
	16.6 Other cash provided (applied)	22,489,079	3,140,031
17.	Net cash from financing and miscellaneous sources (Lines 16.1 to 16.4 minus Line 16.5 plus Line 16.6)	42,489,079	3,140,031
	RECONCILIATION OF CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS		
18.	Net change in cash, cash equivalents and short-term investments (Line 11, plus Lines 15 and 17)	70,449,062	10,413,022
19.	Cash, cash equivalents and short-term investments:	, -,	, -, ==
	19.1 Beginning of year	26,070,055	15,657,033
			, ,

Note: Supplemental disclosures of cash flow information for non-cash transactions:		
20.0001.Non Cash Intercompany Capital contribution	0	10,000,000

# **ANALYSIS OF OPERATIONS BY LINES OF BUSINESS**

			AL I SIS C		TIONS D	I LINES	JE DUSINI	_00			
		1	2	3	4	5	6 Federal Employees	7 Title	8 Title	9	10
			Comprehensive	Medicare	Dental	Vision	Health	XVIII	XIX		Other
		Total	(Hospital & Medical)	Supplement	Only	Only	Benefits Plan	Medicare	Medicaid	Other Health	Non-Health
1.	Net premium income		0	0	(	)	0	399.347.576	0	0	
2.	•			•					•	•	
	rate credit	246,986	0	0	(	)	0	246,986	0	0	
3.	Fee-for-service (net of \$							, l			
	medical expenses)	0	0	0	(	)	0	0	0	0	XXX
4.		0	0	0	(	)	0	0	0	0	XXX
5.	Aggregate write-ins for other health care related revenues	0	0	0	(	0	0	0	0	0	XXX
6.	Aggregate write-ins for other non-health care related revenues	0	xxx	XXX	XXX	XXX	xxx	XXX	XXX	XXX	
7		399,594,562						399.594.562			
7. 8.	Hospital/medical benefits	259, 759, 105		۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰		,u	V	259,759,105	۰		XXX
9.	Other professional services	259,759,105		0		,	V	16,658,953	0		XXX
9. 10.	Outside referrals			0		,	V	9 . 199 . 628	0		XXX
11.		17,866,051	0	٥		,	0	17,866,051	۰	٠	XXX
12.	Prescription drugs	32,214,598	0			,	0	32.214.598	0	٠	XXX
13.	Aggregate write-ins for other hospital and medical	0	0			0	n	0	0	٥	XXX
14.	1	15,986,872	0			1	n	15.986.872	۰	٥	XXX
15.	Subtotal (Lines 8 to 14)	351,685,207	0			,	n	351,685,207	0	٥	XXX
16.	Net reinsurance recoveries	9,224,905	0			1	0	9.224.905	۰	٠	XXX
17.	Total medical and hospital (Lines 15 minus 16)	342.460.302	0			0	0	342.460.302	۰	٠	XXX
18.	Non-health claims (net)	0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	
19.	, ,										
	\$5,733,367 cost containment expenses	7,832,640	0	0	(	)	0	7,832,640	0	0	
20.	General administrative expenses	41,036,215	0	0	(	)	0	41,036,215	0	0	
21.	Increase in reserves for accident and health contracts	6,533,095	0	0	(		0	6,533,095	0	0	XXX
22.	Increase in reserves for life contracts	0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	
23.	3 ,	397,862,252	0	0	(	0	0	397,862,252	0	0	0
24.	Total underwriting gain or (loss) (Line 7 minus Line 23)	1,732,310	0	0	(	0	0	1,732,310	0	0	0
0=04	DETAILS OF WRITE-INS										2004
0501.											XXX
0502.											XXX
0503.											XXX
0598.	Summary of remaining write-ins for Line 5 from overflow page	^		^	,	,			_	Δ.	XXX
0599.	. •		0			)	0		۰	٠	XXX
0601.	Totals (Lines 0501 thru 0503 plus 0598) (Line 5 above)	U	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	^^^
0601.			XXX	XXX	XXX	XXX	XXX	XXX	XXXXXX	XXX	
0602.			XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	
	Summary of remaining write-ins for Line 6 from overflow			^^^							
5030.	page	0	xxx	XXX	XXX	xxx	xxx	XXX	XXX	XXX	0
0699.	Totals (Lines 0601 thru 0603 plus 0698) (Line 6 above)	0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	0
1301.											XXX
1302.											XXX
1303.											XXX
1398.	Summary of remaining write-ins for Line 13 from	0		0	,				_	0	xxx
1200	overflow page	٠		۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰		,			ا ۱		XXX
1399.	Totals (Littles 1301 titlu 1303 plus 1396) (Little 13 above)	U	0	U	(	, 1	. 0	U	U	0	

7

#### m

## ANNUAL STATEMENT FOR THE YEAR 2022 OF THE Aetna Health of Michigan Inc.

# **UNDERWRITING AND INVESTMENT EXHIBIT**

PART 1 - PREMILIMS

PARI 1 - PREMIUMS	1	2	3	4
Line of Business	Direct Business	Reinsurance Assumed	Reinsurance Ceded	Net Premium Income (Cols. 1 + 2 - 3)
Comprehensive (hospital and medical) individual				0
Comprehensive (hospital and medical) group				0
3. Medicare Supplement				0
4. Dental only				0
5. Vision only				0
6. Federal Employees Health Benefits Plan	0			0
7. Title XVIII - Medicare	409,687,337		10,339,760	399,347,577
8. Title XIX - Medicaid	0			0
9. Credit A&H				0
10. Disability Income				0
11. Long-Term Care				0
12. Other health				0
13. Health subtotal (Lines 1 through 12)	409,687,337	0	10,339,760	399,347,577
14. Life	0			0
15. Property/casualty	0			0
16. Totals (Lines 13 to 15)	409,687,337	0	10,339,760	399,347,577

# **UNDERWRITING AND INVESTMENT EXHIBIT**

PART 2 - CLAIMS INCURRED DURING THE YEAR

					F	PART 2 - CLAIM	IS INCURRED	DURING THE Y	EAR						
		1	Compreh (Hospital &		4	5	6	7	8	9	10	11	12	13	14
		Total	2 Individual	3 Group	Medicare Supplement	Dental Only	Vision Only	Federal Employees Health Benefits Plan	Title XVIII Medicare	Title XIX Medicaid	Credit A&H	Disability Income	Long-Term Care	Other Health	Other Non-Health
1.	Payments during the year:			J. J. J.									5 55		
	1.1 Direct	308,464,377	0	0	0	0	0	0	308,464,377	0	0	0	0	0	0
	1.2 Reinsurance assumed	0	0 l.	0	0	0	0	0	0	0	0	0	0	0	0
	1.3 Reinsurance ceded	8,201,452	0	0	0	0	0	0	8,201,452	0	0	0	0	0	0
	1.4 Net	300,262,925	0	0	0	0	0	0	300,262,925	0	0	0	0	0	0
2.	Paid medical incentive pools and														
	bonuses	8,261,289	0	0	0	0	0	0	8,261,289	0	0	0	0	0	0
3.	Claim liability December 31, current year from Part 2A:	47, 450, 704							47, 450, 704						
	3.1 Direct	47, 156, 781	0	0	0	0	0	0	47, 156, 781	0	0	0	0	0	0
	3.2 Reinsurance assumed	0							4 000 0 :=						
	3.3 Reinsurance ceded	1,323,017	0	0	0	0	0	J0	1,323,017	J0	J0	0	J0	0	0
	3.4 Net	45,833,764	0	0	0	0	0	0	45,833,764	0	0	0	0	0	0
4.	Claim reserve December 31, current year from Part 2D: 4.1 Direct	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	4.1 Direct				٥٥	n	0		0		0			٥	٥
	4.3 Reinsurance ceded				٥٥	n	0		0					0	٥
	4.4 Net					0	0		0	0	0	0	0	0	٥
_	Accrued medical incentive pools and	0			0	0	0		0	u		0	u	0	0
5.	bonuses, current year	9,502,792	0	0	0	0	0	0	9,502,792	0	0	0	0	0	0
6.	Net health care receivables (a)	4,543,844	0	0	0	0	0	0	4,543,844	0	0	0	0	0	0
	Amounts recoverable from reinsurers	+,0+0,0++							4,040,044						
7.	December 31, current year	0	0	0	0	0	0	0	0	0	0	0	0	0	0
8.	Claim liability December 31, prior year from Part 2A:	45.000.000													
	8.1 Direct	15,378,979	0	0	0	0	0	0	15,378,979	0	0	0	0	0	0
	8.2 Reinsurance assumed	0	0	0							0	0	0		
	8.3 Reinsurance ceded	299,564	0	0	0	0	0	0	299,564	0	0	0	0	0	0
	8.4 Net	15,079,415	0	0	0	0	0	0	15,079,415	0	0	0	0	0	0
9.	Claim reserve December 31, prior year from Part 2D: 9.1 Direct	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		0 				0	0		0	0	0	0	0	0	
	9.2 Reinsurance assumed	0				0	0		0	0	0	0	0	0	
	9.3 Reinsurance ceded	0 	<u> </u>	0		0	0	ļ	0	J	0	0	0	0	
40	9.4 Net	0		0	0	0	0	J	J	J	J	0	J0	0	0
	Accrued medical incentive pools and bonuses, prior year	1,777,209	0	0	0	0	0	0	1,777,209	0	0	0	0	0	0
	Amounts recoverable from reinsurers December 31, prior year	0	0	0	0	0	0	0	0	0	0	0	0	0	0
12.	Incurred Benefits: 12.1 Direct	335,698,335	0	0	0	0	0	0	335,698,335	0	0		0	0	0
	12.2 Reinsurance assumed	0	0	0	0	0	0	J0	0	J0	0		0	0	0
	12.3 Reinsurance ceded	9,224,905	0	0	0	0	0	0	9,224,905	0	0		0	0	0
	12.4 Net	326,473,430	0	0	0	0	0	0	326,473,430	0	0	0	0	0	0
13.	Incurred medical incentive pools and bonuses	15,986,872	0	0	0	0	0	0	15,986,872	0	0	0	0	0	0

<sup>(</sup>a) Excludes \$ ...... loans or advances to providers not yet expensed.

# **UNDERWRITING AND INVESTMENT EXHIBIT**

PART 2A - CLAIMS LIABILITY END OF CURRENT YEAR

	1 4	0			T 2A - CLAIMS		D OF CURREN			40	- 44	10	40	1 44
	1	Compre (Hospital &	nensive Medical)	4	5	6	7	8	9	10	11	12	13	14
		2	3				Federal							
				Medicare			Employees Health	Title VVIII	Title VIV		Dischilit	Long Torre		Other
	Total	Individual	Group	Supplement	Dental Only	Vision Only	Benefits Plan	Title XVIII Medicare	Title XIX Medicaid	Credit A&H	Disability Income	Long-Term Care	Other Health	Non-Health
Reported in Process of Adjustment:														
1.1 Direct	8,501,628	0	0	0	0	0	0	8,501,628	0	0	0	0	0	0
1.2 Reinsurance assumed	0	0		0	0	0	0	0	0	0	0	0	0	0
1.3 Reinsurance ceded				0	0	0	0	0	0	0	0	0	0	0
1.4 Net			0							0	0	0	0	0
Incurred but Unreported:														
2.1 Direct	38,655,153	0	0	0	0	0	0	38,655,153	0	0	0	0	0	0
2.2 Reinsurance assumed	0	0	0	0	0	0	0		0	0	0	0	0	0
2.3 Reinsurance ceded		0		0	0	0	0	1,323,017	0	0	0	0	0	0
2.4 Net		0			0			37,332,136	0	0	0			0
Amounts Withheld from Paid Claims and Capitations:														
3.1 Direct	0	0	0	0	0	0	0	0	0	0	0	0	0	0
3.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0	0	0	0	0
3.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	0	0	0	0	0
3.4 Net	0	0	0	0	0	0	0	0	0	0	0	0	0	0
4. TOTALS:														
4.1 Direct	47,156,781	0	0	0	0	0	0	47,156,781	0	0	0	0	0	0
4.2 Reinsurance assumed	0	0			0	0	0	0	0	0	0	0	0	0
4.3 Reinsurance ceded	1,323,017	0	0	0	0	0	0	1,323,017	0	0	0	0	0	0
4.4 Net	45,833,764	0	0	0	0	0	0	45,833,764	0	0	0	0	0	0

# **UNDERWRITING AND INVESTMENT EXHIBIT**

PART 2B - ANALYSIS OF CLAIMS UNPAID - PRIOR YEAR - NET OF REINSURANCE

	Claims Paid D	Ouring the Year	Claim Reserve a December 31 o		5	6
	1	2	3	4		Estimated Claim Reserve and Claim
Line of Business	On Claims Incurred Prior to January 1 of Current Year	On Claims Incurred During the Year	On Claims Unpaid December 31 of Prior Year	On Claims Incurred During the Year	Claims Incurred In Prior Years (Columns 1 + 3)	Liability December 31 of Prior Year
Comprehensive (hospital and medical) individual	0	0	0	0	0	0
Comprehensive (hospital and medical) group	0	0	0	0	0	0
3. Medicare Supplement	0	0	0	0	0	0
4. Dental Only	0	0	0	0	0	0
5. Vision Only	0	0	0	0	0	0
6. Federal Employees Health Benefits Plan	0	0	0	0	0	0
7. Title XVIII - Medicare	10,066,108	290 , 196 , 817	118,827	45,714,937	10 , 184 , 935	15,079,415
8 Title XIX - Medicaid	0	0	0	0	0	0
9. Credit A&H					0	
10. Disability Income					0	
11. Long-Term Care					0	
12. Other health	0	0	0	0	0	0
13. Health subtotal (Lines 1 to 12)		290 , 196 , 817	118,827	45,714,937	10 , 184 , 935	15,079,415
14. Health care receivables (a)	0	6,021,228	0	0	0	1,477,384
15. Other non-health	0	0	0	0	0	0
16. Medical incentive pools and bonus amounts	(1,210,501)	9,471,790	563,864	8,938,928	(646,637)	1,777,209
17. Totals (Lines 13 - 14 + 15 + 16)	8,855,607	293,647,379	682,691	54,653,865	9,538,298	15,379,240

<sup>(</sup>a) Excludes \$ ...... loans or advances to providers not yet expensed.

## **UNDERWRITING AND INVESTMENT EXHIBIT**

# PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS (\$000 Omitted)

Section A - Paid Health Claims - Comprehensive (Hospital & Medical)

		Cumulative Net Amounts Paid					
		1	2	3	4	5	
	Year in Which Losses Were Incurred	2018	2019	2020	2021	2022	
1.	Prior	0		.0 0.	0		
2.	2018	(2)		(2) (2)	(2)	(2)	
3.	2019	XXX					
4.	2020	XXX	XXX	(27)	(27)	(27	
5.	2021	XXX	XXX	XXX			
6.	2022	XXX	XXX	XXX	XXX		

Section B - Incurred Health Claims - Comprehensive (Hospital & Medical)

	Sum of Cumulative N	Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonu Outstanding at End of Year						
Year in Which Losses Were Incurred	1 2018	2 2019	3 2020	4 2021	5 2022			
1. Prior	0	0	0	0				
2. 2018	(2)	(2)	(2)	(2)	(2)			
3. 2019	XXX							
4. 2020	XXX	XXX	(27)	(27)	(27)			
5. 2021	XXX	XXX	XXX					
6. 2022	XXX	XXX	XXX	XXX				

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Comprehensive (Hospital & Medical)

		1	2	3	4	5	6	7	8	9	10	i
						Claim and Claim				Total Claims and		i
	Years in which					Adjustment Expense			Unpaid Claims	Claims Adjustment		i
	Premiums were Earned and Claims			Claim Adjustment	(Col. 3/2)	Payments	(Col. 5/1)		Adjustment	Expense Incurred	(Col. 9/1)	ı
	were Incurred	Premiums Earned	Claims Payment	Expense Payments	Percent	(Col. 2 + 3)	Percent	Claims Unpaid	Expenses	(Col. 5+7+8)	Percent	i
1	2018		(2)			(2)	0.0			(2)	0.0	i
2	2. 2019		, ,		0.0	0	0.0			0	0.0	i
3	3 2020		(27)		0.0	(27)	0.0			(27)	0.0	ı
4	L 2021		(= )		0.0	0	0.0			0	0.0	ł
5	5. 2022				0.0	0	0.0			0	0.0	l

# **UNDERWRITING AND INVESTMENT EXHIBIT**

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS (\$000 Omitted)

Section A - Paid Health Claims - Medicare Supplement

Occion A-1 and realth Olaims - medicare oupplement	•				
	Cumulative Net Amounts Paid				
	1	2	3	4	5
Year in Which Losses Were Incurred	2018	2019	2020	2021	2022
1. Prior					
2. 2018					
3 2019	XXX				
4. 2020	XXX	XXX			
5 2021	XXX	XXX	XXX		
0. 2021					
6. 2022	XXX	XXX	XXX	XXX	

Section B - Incurred Health Claims - Medicare Supplement

econom B mountain channe meancare cappions							
	Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool a Outstanding at End of Year						
	1	2	3	4	5		
Year in Which Losses Were Incurred	2018	2019	2020	2021	2022		
1. Prior							
2. 2018							
3. 2019	XXX						
4 2020	xxx	XXX					
5. 2021	XXX	XXX	XXX				
6. 2022	XXX	XXX	XXX	XXX			

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Medicare Supplement

	1	2	3	4	5	6	7	8	9	10
					Claim and Claim				Total Claims and	
Years in which					Adjustment Expense			Unpaid Claims	Claims Adjustment	
Premiums were Earned and Claims			Claim Adiustment	(Col. 3/2)	Payments	(Col. 5/1)		Adjustment	Expense Incurred	(Col. 9/1)
were Incurred	Premiums Earned	Claims Payment	ense ymer	Perc		Percent	Claims Unpaid	Expenses	(Col. 5+7+8)	Percent
1. 2018										
2. 2019										
3. 2020										
4. 2021				<b></b>						
5. 2022										

# **UNDERWRITING AND INVESTMENT EXHIBIT**

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS (\$000 Omitted)

Section A - Paid Health Claims - Dental Only

=======================================	Cumulative Net Amounts Paid				
	1	2	3	4	5
Year in Which Losses Were Incurred	2018	2019	2020	2021	2022
1. Prior					
2. 2018					
3. 2019	XXX				
4. 2020	XXX	XXX			
5. 2021	XXX	XXX	xxx		
6. 2022	XXX	XXX	XXX	XXX	

Section B - Incurred Health Claims - Dental Only

Total Daniel Dan						
	Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool Outstanding at End of Year					
	1	2	3	4	5	
Year in Which Losses Were Incurred	2018	2019	2020	2021	2022	
1. Prior						
2. 2018						
3. 2019	xxx					
4. 2020	XXX	XXX				
5. 2021	XXX	xxx	XXX			
6 2022	XXX	XXX	XXX	XXX		

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Dental Only

		1	2	3	4	5	6	7	8	9	10
						Claim and Claim				Total Claims and	1
	Years in which					Adjustment Expense			Unpaid Claims	Claims Adjustment	1
	Premiums were Earned and Claims			Claim Adiustment	(Col. 3/2)	Payments	(Col. 5/1)		Adjustment	Expense Incurred	(Col. 9/1)
	were Incurred	Premiums Earned	Claims Payment	ense ymer	Perc		Percent	Claims Unpaid	Expenses	(Col. 5+7+8)	Percent
1	2018										
2	2019										
2.	2020					,					
3.						·····			•••••		
4.	2021				<b></b>						
5.	2022										

# **UNDERWRITING AND INVESTMENT EXHIBIT**

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS (\$000 Omitted)

Section A - Paid Health Claims - Vision Only

	Cumulative Net Amounts Paid				
	1	2	3	4	5
Year in Which Losses Were Incurred	2018	2019	2020	2021	2022
1. Prior					
2. 2018					
3. 2019	XXX				
4. 2020	XXX	XXX			
5. 2021	XXX	XXX	XXX		
6. 2022	XXX	XXX	XXX	XXX	

Section B - Incurred Health Claims - Vision Only

	Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool Outstanding at End of Year					
	1	2	3	4	5	
Year in Which Losses Were Incurred	2018	2019	2020	2021	2022	
1. Prior						
2. 2018						
3. 2019	xxx					
4. 2020	xxx	XXX				
5. 2021	XXX	xxx	XXX			
6. 2022	XXX	XXX	XXX	XXX		

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Vision Only

		1	2	3	4	5	6	7	8	9	10
						Claim and Claim				Total Claims and	1
	Years in which					Adjustment Expense			Unpaid Claims	Claims Adjustment	1
	Premiums were Earned and Claims			Claim Adiustment	(Col. 3/2)	Payments	(Col. 5/1)		Adjustment	Expense Incurred	(Col. 9/1)
	were Incurred	Premiums Earned	Claims Payment	ense ymer	Perc		Percent	Claims Unpaid	Expenses	(Col. 5+7+8)	Percent
1	2018										
2	2019										
2.	2020					,					
3.						·····			•••••		
4.	2021				<b></b>						
5.	2022										

# **UNDERWRITING AND INVESTMENT EXHIBIT**

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS (\$000 Omitted)

Section A - Paid Health Claims - Federal Employees Health Benefits Plan Premium

Section A - Paid Health Glaims - Federal Employees Health Benefit		Cı	ımulative Net Amounts F	Paid	
	4	0	andative Net Amounts i	aiu	
	1	2	3	4	5
Year in Which Losses Were Incurred	2018	2019	2020	2021	2022
1. Prior					
2. 2018					
	••••				
3. 2019	XXX				
4. 2020	XXX	XXX			
			2001		
5. 2021	XXX	XXX	XXX		
6. 2022	XXX	XXX	XXX	XXX	

Section B - Incurred Health Claims - Federal Employees Health Benefits Plan Premium

Occion B - incurred ricaliti olalina - i ederal Employees ricaliti Bener							
	Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive P Outstanding at End of Year						
	1 2 3 4						
Year in Which Losses Were Incurred	2018	2019	2020	2021	2022		
1. Prior							
2. 2018							
3. 2019	XXX						
4. 2020	XXX	xxx					
5. 2021	XXX	XXX	XXX				
6. 2022	XXX	XXX	XXX	XXX			

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Federal Employees Health Benefits Plan Premium

		1	2	3	4	5	6	7	8	9	10
						Claim and Claim				Total Claims and	
	Years in which					Adjustment Expense			Unpaid Claims	Claims Adjustment	
	Premiums were Earned and Claims			Claim Adiustment	(Col. 3/2)	Payments	(Col. 5/1)		Adjustment	Expense Incurred	(Col. 9/1)
	were Incurred	Premiums Earned	Claims Payment	ense ymer	Perc		Percent	Claims Unpaid	Expenses	(Col. 5+7+8)	Percent
1	2018										
2	2019										
۷.	2010										
3.	2020										
4.	2021										
5.	2022				_						

## **UNDERWRITING AND INVESTMENT EXHIBIT**

# PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS (\$000 Omitted)

Section A - Paid Health Claims - Title XVIII

			C	umulative Net Amounts F	aid	
		1	2	3	4	5
	Year in Which Losses Were Incurred	2018	2019	2020	2021	2022
1.	Prior	0	0	00	0	
2.	2018					
3.	2019	XXX				
4.	2020	XXX	XXX		23,070	23,070
5.	2021	XXX	XXX	XXX	97,295	106, 151
6.	2022	XXX	XXX	XXX	XXX	293,647

#### Section B - Incurred Health Claims - Title XVIII

	Sum of Cumulative Net	Amount Paid and Cla	nim Liability, Claim Rese utstanding at End of Ye	erve and Medical Incenti ar	ve Pool and Bonuses
	1 2 3 4				
Year in Which Losses Were Incurred	2018	2019	2020	2021	2022
1. Prior	0	0	0	0	
2. 2018					
3. 2019	XXX				
4. 2020	XXX	XXX	23,690	26,257	26,257
5. 2021	XXX	XXX	XXX	114,060	123,598
6. 2022	XXX	XXX	XXX	XXX	348,301

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Title XVIII

		1	2	3	4	5 Claim and Claim	6	7	8	9 Total Claims and	10
	Years in which					Adjustment Expense			Unpaid Claims	Claims Adjustment	
	Premiums were Earned and Claims were Incurred	Premiums Earned	Claims Payment	Claim Adjustment Expense Payments	(Col. 3/2) Percent	Payments (Col. 2 + 3)	(Col. 5/1) Percent	Claims Unpaid	Adjustment Expenses	Expense Incurred (Col. 5+7+8)	(Col. 9/1) Percent
1.	2018				0.0	0	0.0			0	0.0
2.	2019				0.0	0	0.0			0	0.0
3.	2020	28,240	23,070		0.0	23,070	81.7			23,070	81.7
4.	2021	126,683	106, 151		0.0	106, 151	83.8	683		106,834	84.3
5.	2022	399,595	293,647	7,301	2.5	300,948	75.3	54,654	770	356,372	89.2

# **UNDERWRITING AND INVESTMENT EXHIBIT**

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS (\$000 Omitted)

Section A - Paid Health Claims - Title XIX

		Cui	mulative Net Amounts F	Paid	
	1	2	3	4	5
Year in Which Losses Were Incurred	2018	2019	2020	2021	2022
1. Prior					
2. 2018					
3. 2019	XXX				
4 2020	XXX	XXX			
5. 2021	XXX	XXX	XXX		
6. 2022	XXX	XXX	XXX	XXX	

#### Section B - Incurred Health Claims - Title XIX

Cotton B mountain dumic market							
	Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Outstanding at End of Year						
	1	2	3	4	5		
Year in Which Losses Were Incurred	2018	2019	2020	2021	2022		
1. Prior							
2. 2018							
3. 2019	XXX						
4. 2020	xxx	XXX					
5. 2021	XXX	XXX	xxx				
6. 2022	XXX	XXX	XXX	XXX			

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Title XIX

	1	2	3	4	5	6	7	8	9	10
					Claim and Claim				Total Claims and	
Years in which					Adjustment Expense			Unpaid Claims	Claims Adjustment	
Premiums were Earned and Claims			Claim Adiustment	(Col. 3/2)	Payments	(Col. 5/1)		Adjustment	Expense Incurred	(Col. 9/1) Percent
were Incurred	Premiums Earned	Claims Payment	yense ymer	Perc		Percent	Claims Unpaid	Expenses	(Col. 5+7+8)	Percent
1. 2018										
2. 2019										
		•••••						•••••		
3. 2020					·····					
4. 2021				<i></i>						
5. 2022										

# **UNDERWRITING AND INVESTMENT EXHIBIT**

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS
(\$000 Omitted)

(\$000 Omitted) Section A - Paid Health Claims - Other

		Cur	mulative Net Amounts F	Paid	
	1	2	3	4	5
Year in Which Losses Were Incurred	2018	2019	2020	2021	2022
1. Prior					
2. 2018					
3. 2019	XXX				
4 2020	XXX	XXX			
5. 2021	XXX	XXX	XXX		
				2007	•••••
6. 2022	XXX	XXX	XXX	XXX	

#### Section B - Incurred Health Claims - Other

	Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentiv Outstanding at End of Year						
	1	2	3	4	5		
Year in Which Losses Were Incurred	2018	2019	2020	2021	2022		
1. Prior							
2. 2018							
3. 2019	XXX						
4. 2020	XXX	XXX					
5. 2021	XXX	XXX	xxx				
6. 2022	XXX	XXX	XXX	XXX			

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Other

		1	2	3	4	5	6	7	8	9	10
						Claim and Claim				Total Claims and	
	Years in which					Adjustment Expense			Unpaid Claims	Claims Adjustment	
	Premiums were Earned and Claims			Claim Adiustment	(Col. 3/2)	Payments	(Col. 5/1)		Adjustment	Expense Incurred	(Col. 9/1)
	were Incurred	Premiums Earned	Claims Payment	ense ymer	Perc		Percent	Claims Unpaid	Expenses	(Col. 5+7+8)	Percent
1	2018										
2	2019										
3	2020										
4	2021				<i></i>					ļ <sup>1</sup>	
5	2022									1	

## **UNDERWRITING AND INVESTMENT EXHIBIT**

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS (\$000 Omitted)

Section A - Paid Health Claims - Grand Total

		Cur	mulative Net Amounts F	Paid	
	1	2	3	4	5
Year in Which Losses Were Incurred	2018	2019	2020	2021	2022
1. Prior	0	0	0	0	0
2. 2018	(2)	(2)	(2)	(2)	(2)
3 2019	XXX	0	0	0	0
4. 2020	XXX	XXX	20.568	23.043	23.043
5. 2021	XXX	XXX	XXX	97.295	106, 151
6. 2022	XXX	XXX	XXX	XXX	293,647

#### Section B - Incurred Health Claims - Grand Total

	Sum of Cumulative Net A	mount Paid and Clain Out	n Liability, Claim Rese standing at End of Yea	rve and Medical Incenti ar	ve Pool and Bonuses
	1	2	3	4	5
Year in Which Losses Were Incurred	2018	2019	2020	2021	2022
1. Prior	0	0	0	0	0
2. 2018	(2)	(2)	(2)	(2)	(2)
3. 2019	XXX	0	0	0	0
4. 2020	XXX	XXX	23,663	26,230	26,230
5. 2021	XXX	XXX	XXX	114,060	123,598
6. 2022	XXX	XXX	XXX	XXX	348,301

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Grand Total

		1	2	3	4	5	6	7	8	9	10
	Years in which					Claim and Claim Adjustment Expense			Unpaid Claims	Total Claims and Claims Adjustment	
	Premiums were Earned and Claims were Incurred	Premiums Earned	Claims Payment	Claim Adjustment Expense Payments	(Col. 3/2) Percent	Payments (Col. 2 + 3)	(Col. 5/1) Percent	Claims Unpaid	Adjustment Expenses	Expense Incurred (Col. 5+7+8)	(Col. 9/1) Percent
1.	2018	0	(2)	0	0.0	(2)	0.0	0	0	(2)	0.0
2.	2019	0	0	0		0	0.0	0	0	0	0.0
3.	2020	28,240	23,043	0	0.0	23,043	81.6	0	0	23,043	81.6
4.	2021	126,683		0	0.0	106, 151	83.8	683	0	106,834	84.3
5.	2022	399,595	293,647	7,301	2.5	300,948	75.3	54,654	770	356,372	89.2

# **UNDERWRITING AND INVESTMENT EXHIBIT**

PART 2D - AGGREGATE RESERVE FOR ACCIDENT AND HEALTH CONTRACTS ONLY

	PART 2D - AGGREGATE RESERVE FOR ACCIDENT AND HEALTH CONTRACTS ONLY													
		1	Compreh (Hospital &		4	5	6	7	8	9	10	11	12	13
			2	3				Federal						
					Madiana			Employees	T:41- \\ \( \( \) \\ \( \) \\ \( \)	T:41 - VIV		Disability.		
		Total	Individual	Group	Medicare Supplement	Dental Only	Vision Only	Health Benefits Plan	Title XVIII Medicare	Title XIX Medicaid	Credit A&H	Disability Income	Long-Term Care	Other
1.	Unearned premium reserves	0												
2.	Additional policy reserves (a)	6,533,095							6,533,095					
3.	Reserve for future contingent benefits	0												
4.	Reserve for rate credits or experience rating refunds													
	(including \$ for investment income)	2,584,666							2,584,666					
5.	Aggregate write-ins for other policy reserves	0	0	0	0	0	0	0	0	0	0	0	0	0
6.	Totals (gross)	9,117,761	0	0	0	0	0	0	9, 117, 761	0	0	0	0	0
7.	Reinsurance ceded	0												
8.	Totals (Net)(Page 3, Line 4)	9, 117, 761	0	0	0	0	0	0	9, 117, 761	0	0	0	0	0
9.	Present value of amounts not yet due on claims	0												
10.	Reserve for future contingent benefits	0												
11.	Aggregate write-ins for other claim reserves	0	0	0	0	0	0	0	0	0	0	0	0	0
12.	Totals (gross)	0	0	0	0	0	0	0	0	0	0	0	0	0
13.	Reinsurance ceded	0												
14.	Totals (Net)(Page 3, Line 7)	0	0	0	0	0	0	0	0	0	0	0	0	0
	DETAILS OF WRITE-INS													
0501.														
0502.														
0503.														
0598.	Summary of remaining write-ins for Line 5 from overflow	0	0	0	0	0	0	0	0	0	0	0	0	0
0599	page Totals (Lines 0501 thru 0503 plus 0598) (Line 5 above)				0					0	0			۰
	- State (Ellies 650 : and 6500 place 6500) (Ellie 6 above)	U	U		U	U	U	U	U	U	0	U	U	U
1102.														
1103.														
	Summary of remaining write-ins for Line 11 from overflow													
	page	0	0	0	0	0	0	0	0	0	0	0	0	0
1199.	Totals (Lines 1101 thru 1103 plus 1198) (Line 11 above)	0	0	0	0	0	0	0	0	0	0	0	0	0

(a) Includes \$ ......6,533,095 premium deficiency reserve.

## **UNDERWRITING AND INVESTMENT EXHIBIT**

PART 3 - ANALYSIS OF EXPENSES

	Т		YSIS OF EXPENSE		4	<i>E</i>
		Claim Adjustme 1	2	3	4	5
		Cost Containment	Other Claim Adjustment	General Administrative	Investment	
		Expenses	Expenses	Expenses	Expenses	Total
1.		25.000	2 222	00.574	204	400 445
	own building)					
2.	Salary, wages and other benefits	3,912,827	1,156,036	9,070,776	29,453	14, 169, 092
3.	Commissions (less \$					
	ceded plus \$assumed)					
4.	Legal fees and expenses					
5.	Certifications and accreditation fees					
6.	Auditing, actuarial and other consulting services					
7.	Traveling expenses					
8.	Marketing and advertising	388 .	28,971	2,192,292	5	2,221,656
9.	Postage, express and telephone	33,107	181,643	748,902	10	963,662
10.	Printing and office supplies	0	54,321	702,111	12	756,444
11.	Occupancy, depreciation and amortization	75,029	23,135	(98, 164)	120	120
12.	Equipment	0	(34,918)	251,621	1	216,704
13.	Cost or depreciation of EDP equipment and software	677	63,936	1,214,171	344	1,279,128
14.	Outsourced services including EDP, claims, and other services	1,374,926	217,495	3,879,383	5,780	5,477,584
15.	Boards, bureaus and association fees	412	144	23,322	164	24,042
16.	Insurance, except on real estate	1,054		246,418	0	247,815
17.	Collection and bank service charges	0	1,318	75,732	1,774	78,824
18.	Group service and administration fees	0	0	0	0	0
19.	Reimbursements by uninsured plans	0	0	0	0	0
20.	Reimbursements from fiscal intermediaries	0	0	0	0	0
21.	Real estate expenses	2	1	205,568	0	205,571
22.	Real estate taxes	0	0	39 , 115	0	39,115
23.	Taxes, licenses and fees:					
	23.1 State and local insurance taxes	0	0	255,573	0	255,573
	23.2 State premium taxes	0	0	0	0	0
	23.3 Regulatory authority licenses and fees		0	3,209	0	3,209
	23.4 Payroll taxes					818,540
	23.5 Other (excluding federal income and real estate taxes)			660		660
24.	Investment expenses not included elsewhere			0	0	0
25.	Aggregate write-ins for expenses	174	17,835	702,172	0	720, 181
26.	Total expenses incurred (Lines 1 to 25)	5.733.367	2,099,273	41,036,215	46.143	(a)48.914.998
27.				0		
28.	Add expenses unpaid December 31, prior year	·	•	0		238 , 168
29.	Amounts receivable relating to uninsured plans.		0		0	2,009
30.	Amounts receivable relating to uninsured plans, current year	0	0	52,315	0	52,315
31.	Total expenses paid (Lines 26 minus 27 plus 28 minus 29 plus 30)	5,347,331	1,953,913	41,086,521	46,143	48,433,908
	DETAILS OF WRITE-INS	0,011,001	1,000,010	11,000,021	70, 170	10,400,000
2501.	Miscellaneous	174	8,184	266,737	0	275,095
2502.	Loss adjustment expense		(5)	ŕ		ŕ
2503.	Interest expense			(95,966)		(86,310)
2598.			, , ,		0	0
2599.		174	17,835	702,172	0	720, 181
(a) Inclu	des management fees of \$		,	n-affiliates.	<u> </u>	720, 101

## **EXHIBIT OF NET INVESTMENT INCOME**

1		1	2
		Collected During Year	<del>-</del>
1.	U.S. government bonds		
1.1	Bonds exempt from U.S. tax		
1.2	Other bonds (unaffiliated)		
1.3	Bonds of affiliates		
2.1	Preferred stocks (unaffiliated)		
2.11	Preferred stocks of affiliates	\ <i>\</i>	
2.2	Common stocks (unaffiliated)		
2.21	Common stocks of affiliates		
3.	Mortgage loans		
4.	Real estate	` '	
5	Contract Loans	` '	
6	Cash, cash equivalents and short-term investments		
7	Derivative instruments		
8.	Other invested assets	* *	
9.	Aggregate write-ins for investment income		
10.	Total gross investment income		1,694,669
11.	Investment expenses		
12.	Investment taxes, licenses and fees, excluding federal income taxes		
13.	Interest expense		
14.	Depreciation on real estate and other invested assets		
15.	Aggregate write-ins for deductions from investment income		
16.	Total deductions (Lines 11 through 15)		
17.	Net investment income (Line 10 minus Line 16)		1,648,526
1	DETAILS OF WRITE-INS		, ,
0901.	Miscellaneous Interest	(50)	(50)
0902.			, ,
0903.			
0998.	Summary of remaining write-ins for Line 9 from overflow page	0	0
0999.	Totals (Lines 0901 thru 0903 plus 0998) (Line 9, above)	(50)	(50)
1501.			
1502.			
1503.			
1598.	Summary of remaining write-ins for Line 15 from overflow page		
1599.	Totals (Lines 1501 thru 1503 plus 1598) (Line 15, above)		0
(a) Inclu	ides \$	66 paid for accrued into	erest on purchases.
(b) Inclu	ides \$ 0 accrual of discount less \$ 0 amortization of premium and less \$	.0 paid for accrued div	ridends on purchases.
(c) Inclu	des \$ 0 accrual of discount less \$	paid for accrued into	erest on purchases.

**EXHIBIT OF CAPITAL GAINS (LOSSES)** 

(e) Includes \$ ......1,305,423 accrual of discount less \$ ...... amortization of premium and less \$ ...... paid for accrued interest on purchases.

... investment expenses and \$ ...... investment taxes, licenses and fees, excluding federal income taxes, attributable to

(d) Includes \$ ...... for company's occupancy of its own buildings; and excludes \$ ..... interest on encumbrances.

(f) Includes \$ ...... accrual of discount less \$ ..... amortization of premium.

(h) Includes \$ ..... interest on surplus notes and \$ ..... interest on capital notes.

(i) Includes \$ \_\_\_\_\_\_0 depreciation on real estate and \$ \_\_\_\_\_ depreciation on other invested assets.

segregated and Separate Accounts.

		_	•	` `		_
		1	2	3	4	5
				Total Realized Capital	Change in	Change in Unrealized
		Realized Gain (Loss)	Other Realized	Gain (Loss)	Unrealized Capital	Foreign Exchange
		On Sales or Maturity	Adjustments	(Columns 1 + 2)	Gain (Loss)	Capital Gain (Loss)
1.	U.S. Government bonds			0	0	0
1.1	Bonds exempt from U.S. tax			0		
1.2	Other bonds (unaffiliated)	0	0	0	0	0
1.3	Bonds of affiliates	0	0	0	0	0
2.1	Preferred stocks (unaffiliated)			0	0	0
2.11	Preferred stocks of affiliates	0	0	0	0	0
2.2	Common stocks (unaffiliated)	0	0	0	(73,805)	0
2.21	Common stocks of affiliates			0	0	0
3.	Mortgage loans			0	0	0
4.	Real estate			0		0
5.				0		
6.	Cash, cash equivalents and short-term investments	69		69		
7.	Derivative instruments			0		
8.	Other invested assets			0	0	0
9.	Aggregate write-ins for capital gains (losses)	0	0	0	0	0
10.	Total capital gains (losses)	69	0	69	(73,805)	0
	DETAILS OF WRITE-INS					
0901.						
0902.						
0903.						
0998.	Summary of remaining write-ins for Line 9 from					
	overflow page	0	0	0	0	0
0999.	Totals (Lines 0901 thru 0903 plus 0998) (Line 9,	0	0	0	n	0
	above)	U	U	U	U	U

# **EXHIBIT OF NON-ADMITTED ASSETS**

	EXHIBIT OF NON-ADMITTE	DASSETS	2	2 3			
		Current Year Total Nonadmitted Assets	Prior Year Total	Change in Total Nonadmitted Assets (Col. 2 - Col. 1)			
1.	Bonds (Schedule D)	0		0			
2.	Stocks (Schedule D):						
	2.1 Preferred stocks	0		0			
	2.2 Common stocks	0		0			
3.	Mortgage loans on real estate (Schedule B):						
	3.1 First liens	0		0			
	3.2 Other than first liens						
4.	Real estate (Schedule A):						
	4.1 Properties occupied by the company	0		0			
	4.2 Properties held for the production of income						
	4.3 Properties held for sale						
5.	Cash (Schedule E - Part 1), cash equivalents (Schedule E - Part 2) and short-term investments (Schedule DA)			_			
6.	Contract loans	0		0			
7.	Derivatives (Schedule DB)						
8.	Other invested assets (Schedule BA)						
9.	Receivables for securities						
10.	Securities lending reinvested collateral assets (Schedule DL)						
11.	Aggregate write-ins for invested assets						
12.	Subtotals, cash and invested assets (Lines 1 to 11)						
13.	Title plants (for Title insurers only)						
13.	Investment income due and accrued						
		0		0			
15.	Premiums and considerations:	160, 200	60, 100	(107.067)			
	15.1 Uncollected premiums and agents' balances in the course of collection						
	15.2 Deferred premiums, agents' balances and installments booked but deferred and not yet due						
	15.3 Accrued retrospective premiums and contracts subject to redetermination	0		0			
16.	Reinsurance:						
	16.1 Amounts recoverable from reinsurers						
	16.2 Funds held by or deposited with reinsured companies						
	16.3 Other amounts receivable under reinsurance contracts						
	Amounts receivable relating to uninsured plans			0			
18.1	Current federal and foreign income tax recoverable and interest thereon			0			
18.2	Net deferred tax asset		,	4,113			
19.	Guaranty funds receivable or on deposit	0		0			
20.	Electronic data processing equipment and software	0		0			
21.	Furniture and equipment, including health care delivery assets	0		0			
22.	Net adjustment in assets and liabilities due to foreign exchange rates	0		0			
23.	Receivable from parent, subsidiaries and affiliates	0		0			
24.	Health care and other amounts receivable	188 , 154		(188,154)			
25.	Aggregate write-ins for other than invested assets	0	0	0			
26.	Total assets excluding Separate Accounts, Segregated Accounts and Protected Cell Accounts (Lines 12 to 25)	357,544	66,236	(291,308)			
27.	From Separate Accounts, Segregated Accounts and Protected Cell Accounts			0			
28.	Total (Lines 26 and 27)	357,544	66,236	(291,308)			
	DETAILS OF WRITE-INS						
1101.							
1102.							
1103.							
1198.	Summary of remaining write-ins for Line 11 from overflow page	0	0	0			
1199.	Totals (Lines 1101 thru 1103 plus 1198)(Line 11 above)	0	0	0			
2501.							
2502.							
2503.							
2598.	Summary of remaining write-ins for Line 25 from overflow page			0			
2599.	Totals (Lines 2501 thru 2503 plus 2598)(Line 25 above)	0	0	0			
∠၁ყყ.	Totals (Lines 2001 tillu 2003 pius 2098)(Line 20 adove)	U	U				

## 17

# **EXHIBIT 1 - ENROLLMENT BY PRODUCT TYPE FOR HEALTH BUSINESS ONLY**

			Total Members at End of			6
Source of Enrollment	1 Prior Year	2 First Quarter	3 Second Quarter	4 Third Quarter	5 Current Year	Current Year Member Months
Health Maintenance Organizations	10,151	20,100	21,425	22,466		256,745
Provider Service Organizations						
3. Preferred Provider Organizations						
4. Point of Service		6,110	7,809	9,164	9,329	92,828
5. Indemnity Only						
Aggregate write-ins for other lines of business	0	0	0	0	0	0
7. Total	12,033	26,210	29,234	31,630	32,028	349,573
DETAILS OF WRITE-INS						
0601.						
0602.						
0603.						
0698. Summary of remaining write-ins for Line 6 from overflow page	0	0	0	0	0	0
0699. Totals (Lines 0601 thru 0603 plus 0698) (Line 6 above)	0	0	0	0	0	0

#### 1. Summary of Significant Accounting Policies and Going Concern

#### A. Accounting Practices

The accompanying statutory financial statements of Aetna Health of Michigan Inc. (the "Company"), indirectly a wholly-owned subsidiary of CVS Health Corporation ("CVS Health"), have been prepared in conformity with accounting practices prescribed or permitted by the Michigan Department of Insurance and Financial Services ("Michigan Department") ("Michigan Accounting Practices"). The Michigan Department recognizes statutory accounting practices prescribed or permitted by the State of Michigan for determining and reporting the financial condition and results of operations of an insurance company, which include accounting practices and procedures adopted by the National Association of Insurance Commissioners' ("NAIC") Accounting Practices and Procedures Manual ("NAIC SAP").

A reconciliation of the Company's net income and capital and surplus between NAIC SAP and practices prescribed and permitted by the State of Michigan for the years ending December 31, 2022 and 2021 is as follows:

		SSAP#	F/S Page	F/S Line #	2022	2021
NET	INCOME					
(1)	Aetna Health of Michigan Inc.					
	state basis (Page 4, Line 32, Columns 2 & 3)	XXX	XXX	XXX	\$ 1,770,344	\$ (1,210,424)
(2)	State Prescribed Practices that are an increase/(decrease) from NAIC SAP:					
(3)	State Permitted Practices that are an increase/(decrease) from NAIC SAP:					
(4)	NAIC SAP (1-2-3=4)	XXX	XXX	XXX	\$ 1,770,344	\$ (1,210,424)
SURP	LUS					
(5)	Aetna Health of Michigan Inc.					
	state basis (Page 3, Line 33, Columns 3 & 4)	XXX	XXX	XXX	\$ 43,998,329	\$ 21,080,350
(6)	State Prescribed Practices that are an increase/(decrease) from NAIC SAP:					
(7)	State Permitted Practices that are an increase/(decrease) from NAIC SAP:					
(8)	NAIC SAP (5-6-7=8)	XXX	XXX	XXX	\$ 43,998,329	\$ 21,080,350

#### B. <u>Use of Estimates in the Preparation of the Financial Statements</u>

The preparation of these financial statements in conformity with Michigan Accounting Practices requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and revenue and expenses. Actual results could differ from those estimates.

#### C. Accounting Policies

The Company applies the following significant accounting policies:

### (1) Cash, Cash Equivalents and Short-Term Investments

Cash, cash equivalents and short-term investments, consisting primarily of money market instruments and other debt issues with an original maturity of up to one year, are carried at amortized cost. Short-term investments consist primarily of investments purchased with an original maturity date of greater than three months but less than one year. Cash equivalents consist of highly liquid instruments, which mature within three months from the date of purchase. The carrying amount of cash, cash equivalents and short-term investments approximates fair value. Cash accounts with positive balances shall not be reported separately from cash accounts with negative balances. If in the aggregate, the reporting entity has a net negative cash balance, it shall be reported as a negative asset and shall not be recorded as a liability.

#### (2) Bonds

Bonds, which include special deposits, are carried at amortized cost except for those bonds with an NAIC designation of 3 through 6, which are carried at the lower of amortized cost or fair value. The amount carried at fair value is not material to the financial statements. Bond premiums and discounts are amortized using the scientific interest method. When quoted prices in active markets for identical assets are available, the Company uses these quoted market prices to determine the fair value of bonds. This is used primarily for U.S. government securities. In other cases where a quoted

market price for identical assets in an active market is either not available or not observable, the Company estimates fair values using valuation methodologies based on available and observable market information or by using a matrix pricing model. If quoted market prices are not available, the Company determines fair value using broker quotes or an internal analysis of each investment's financial performance and cash flow projections. The Company had no investments where fair value was determined using broker quotes or an internal analysis of financial performance and cash flow projections at December 31, 2022 or 2021. Bonds include all investments whose maturity is greater than one year when purchased. All adjustments between amortized cost and carrying value are reflected in unrealized capital gains and losses and are reported as direct adjustments to surplus.

Bonds are recorded as purchases or sales on the trade date.

The Company analyzes all relevant facts and circumstances for each investment when performing its analysis to determine whether an OTTI exists. Among the factors considered in evaluating whether a decline is other-than-temporary, management considers whether the decline in fair value results from a change in the quality of the investment security itself, whether the decline results from a downward movement in the market as a whole, the prospects for realizing the carrying value of the bond based on the investee's current and short-term prospects for recovery and other factors. The risks inherent in assessing the impairment of an investment include the risk that market factors may differ from the Company's expectations and the risk that facts and circumstances factored into its assessment may change with the passage of time. Unexpected changes to market factors and circumstances that were not present in past reporting periods may result in a current period decision to sell securities that were not other-than-temporarily-impaired in prior reporting periods.

The Company had no Securities Valuation Office-identified investments that are being reported at a different measurement method from the prior year annual statement.

#### (3) Common Stocks

Common stocks are recorded as purchases or sales on the trade date. Common stocks are carried at fair value. Declines in the cost basis deemed to be OTTI are recognized as realized capital losses.

#### (4) Preferred Stocks

The Company did not own any preferred stock at December 31, 2022 or 2021.

#### (5) Mortgage Loans

The Company did not have any mortgage loans at December 31, 2022 or 2021.

#### (6) Loan-Backed and Structured Securities

The Company did not have any loan-backed and structured securities at December 31, 2022 or 2021.

### (7) Investments in Subsidiaries, Controlled or Affiliated Companies

The Company did not have any investments in subsidiaries, controlled or affiliated companies at December 31, 2022 or 2021.

## (8) Investments in Joint Ventures, Partnerships and Limited Liability Companies

The Company did not have any investments in any joint ventures, partnerships and limited liability companies at December 31, 2022 or 2021.

### (9) Derivatives

The Company did not have any derivatives at December 31, 2022 or 2021.

#### (10) Aggregate Health Policy Reserves and Related Expenses

Premium deficiency reserves ("PDR") are recognized when it is probable that the expected future hospital and medical costs, including maintenance costs, will exceed anticipated future premiums and reinsurance recoveries on existing contracts. Anticipated investment income is not considered in the calculation of any PDR. For purposes of calculating a PDR, contracts are grouped in a manner consistent with the method of acquiring, servicing and measuring the profitability of such contracts.

Unearned premium reserves ("UEP") are recognized for premiums that are recorded by the Company that have not been earned as of the statement date. The Company had no UEP at December 31, 2022 or 2021.

The Company is required to make premium rebate payments to customers that are enrolled under certain health insurance policies if specific minimum annual medical loss ratios ("MLR") were not met in the prior year. The Company had no MLR rebates at December 31, 2022. The Company's results for full year December 31, 2021 include estimates of \$246,986 of minimum MLR rebates, which were included in aggregate health policy reserves in the Statutory Statements of Liabilities and Capital and Surplus.

For Medicare plans, the Company's annual contract with Centers for Medicare & Medicaid Services ("CMS") provides a risk-sharing arrangement to limit exposure to unexpected expenses. The risk-sharing arrangement provides a risk corridor whereby the amount the Company received in premiums from members and CMS based on its annual bid is compared to actual drug costs incurred during the contract year. Based on the risk corridor provision and Part D activity-to-date, estimated risk-sharing payables of \$2,349,202 and \$342,750 were included in aggregate health policy reserves in the Statutory Statements of Liabilities, Capital and Surplus at December 31, 2022 and 2021, respectively.

The Company reported liabilities associated with contracts subject to redetermination as aggregate health policy reserves in accordance with SSAP No. 54 - Revised - *Individual and Group and Accident Health Contracts* ("SSAP No. 54"). Liabilities associated with estimated adjustments to premium payments to the Company's Medicare plans based on the health status of its Medicare members are included as part of the Company's contracts subject to redetermination. Amounts related to these liabilities are \$235,463 and \$59,711 and are included in aggregate health policy reserves at December 31, 2022 and 2021, respectively.

#### (11) Hospital and Medical Costs and Claims Adjustment Expenses and Related Reserves

Hospital and medical costs consist principally of fee-for-service medical claims and capitation costs. Claims unpaid and aggregate health claim reserves include the Company's estimate of payments to be made on claims reported but not yet paid and for health care services rendered to enrollees but not yet reported to the Company as of the Statutory Statements of Assets and Liabilities, Capital and Surplus date. Such estimates are developed using actuarial principles and assumptions, which consider, among other things, historical and projected claim submission and processing payment patterns, medical cost trends, historical utilization of health care services, claim inventory levels, medical inflation, contract requirement changes in membership and product mix, seasonality and other relevant factors. The Company reflects changes in estimates in hospital and medical costs in the Statutory Statements of Revenue and Expenses in the period they are determined. Capitation costs, which are recorded in hospital and medical expenses in the Statutory Statements of Revenue and Expenses, represent contractual monthly fees paid to participating physicians and other medical providers for providing medical care, regardless of the medical services provided to the enrollee.

The Company uses the triangulation method to estimate reserves for claims incurred but not reported. The method of triangulation makes estimates of completion factors that are then applied to the total paid claims (net of coordination of benefits) to date for each incurral month. This provides an estimate of the total projected incurred claims and total amount outstanding or claims incurred but not reported (claims unpaid). For the most current dates of service where there is insufficient paid claim data to rely solely on the triangulation method, the Company examines cost and utilization trends as well as environmental factors, plan changes, provider contracts, changes in membership and/or benefits, and historical seasonal patterns to estimate the reserve required for these months.

Claims adjustment expenses, which include cost containment expenses, represent the costs incurred related to the claim settlement process such as costs to record, process and adjust claims. These expenses are included in the Company's management agreement with an affiliate described in Note 10.

#### (12) Capitalization Policy

The Company has not modified its capitalization policy from the prior period.

### (13) Pharmaceutical Rebate Receivables

The Company estimates pharmaceutical rebate receivables based upon historical payment trends, actual utilization and other variables. Pharmaceutical rebates for a quarter are billed to the vendor within one month of the completion of the quarter with any adjustment to previously recorded amounts reflected at the time of billing. The Company reports pharmaceutical rebate receivables as health care receivables. Pharmacy rebate receivables not in accordance with SSAP No. 84 – *Health Care and Government Insured Plan Receivables* or are over 90 days past due are nonadmitted. All rebates are processed and settled monthly with an affiliated entity, including adjustments to previously billed periods. The pharmaceutical rebate receivables are more fully discussed in Note 28.

#### (14) Premiums and Amounts Due and Unpaid

Premium revenue for prepaid health care products is recognized as income in the month in which enrollees are entitled to health care services. Premiums collected before the effective period are reported as premiums received in advance. Premiums related to unexpired contractual coverage periods are reported as unearned premiums and are included in aggregate health policy reserves in the Statutory Statements of Liabilities, Capital and Surplus.

Nonadmitted amounts consist of all premiums due and unpaid greater than 90 days past due, with the exception of amounts due under government insured plans, which may be admitted assets under certain circumstances. In addition, for any customer for which the premiums due and unpaid greater than 90 days past due is more than a de minimus portion of the entire balance of premiums due and unpaid for that customer, the entire balance of premiums due and unpaid for that customer is nonadmitted. Management also performs a specific review of accounts and based on the results of the review, additional amounts may be nonadmitted. Uncollectible amounts are generally written-off and charged to revenue in the period in which the customer reconciliations are completed and agreed to by the customer (retroactivity) or when the account is determined to be uncollectible by the Company.

Through the Company's Medicare Advantage Part D annual contract with CMS, the Company receives monthly premium payments from CMS and members, as determined by the Company's annual bid process. The Company recognizes the revenue related to the CMS contract ratably over the term of its annual contract.

The CMS payment is subject to risk sharing provisions through the CMS risk corridor provision, which is accounted for as a retrospectively rated contract in accordance with SSAP No. 66 - *Retrospectively Rated Contracts*. Receivables related to the CMS risk corridor provision are included in accrued retrospective premiums and contracts subject to redetermination on the Statutory Statements of Assets.

The Company's CMS payment is also subject to the CMS risk adjustment process for each member, which is accounted for as a contract subject to redetermination in accordance with SSAP No. 54. Receivables related to the CMS risk adjustment process are included in accrued retrospective premiums and contracts subject to redetermination on the Statutory Statements of Assets.

### (15) Aggregate Health Claim Reserves

The reserve for future contingent benefits includes the estimated cost of services that will continue to be incurred after the Statutory Statements of Liabilities, Capital and Surplus date if the Company is obligated to pay for such services in accordance with contract provisions or regulatory requirements. These balances are recorded in aggregate health claim reserves in the Statutory Statements of Liabilities, Capital and Surplus and are estimated using a percentage of current hospital and medical costs, which is based on the Company's historical cost experience.

#### (16) Investment Income Due and Accrued

Accrued investment income consists primarily of interest. Interest is recognized on an accrual basis and dividends are recorded as earned on the ex-dividend date. Due and accrued income is not recorded on: (a) bonds in default; and (b) bonds delinquent more than 90 days or where collection of interest is improbable. At December 31, 2022 and 2021, the Company did not have any nonadmitted investment income due and accrued.

#### (17) Covered and Uncovered Expenses and Related Liabilities

Covered expenses and related liabilities represent costs for health care expenses for which a member is not responsible in the event of the insolvency of the Company. Uncovered expenses and related liabilities represent costs to the Company for health care services that are the obligation of the Company and for which a member may also be liable in the event of the Company's insolvency.

#### (18) Reinsurance

In the normal course of business, the Company seeks to reduce the loss that may arise from catastrophes or other events that cause unfavorable underwriting results and to help balance its risks and capital by reinsuring certain levels of risk with other insurance enterprises. The reinsurance coverage does not relieve the Company of its primary obligations. Reinsurance premiums and reserves related to reinsured business are accounted for on a basis consistent with those used in accounting for the original policies issued and the terms of the reinsurance contracts. Premiums and claims ceded and the related unpaid reserves have been reported as reductions of these items. The reinsurance agreements are more fully discussed in Note 23.

#### (19) Federal and State Income Taxes

Aetna Inc. ("Aetna") and its wholly-owned subsidiaries are included in the consolidated federal income tax return of its ultimate parent company, CVS Health, pursuant to the terms of a tax sharing agreement. In accordance with the agreement, the Company's current federal and state income tax provisions are generally computed as if the Company were filing a separate federal and state income tax return; current income tax benefits, including those resulting from net operating losses, are recognized to the extent expected to be realized in the consolidated return. Pursuant to the agreement, the Company has the enforceable right to recoup federal and state income taxes paid in prior years in the event of future net losses, which it may incur, or to recoup its net losses carried forward as an offset to future net income subject to federal and state income taxes.

Income taxes are accounted for under the asset and liability method. Deferred income tax assets ("DTAs") and liabilities ("DTLs") represent the expected future tax consequences of temporary differences generated by statutory accounting as defined in SSAP No. 101 - *Income Taxes*. DTAs and DTLs are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. DTAs and DTLs are computed by means of identifying temporary differences which are measured using a balance sheet approach whereby statutory and tax basis balance sheets are compared. Current income tax recoverables include all current income taxes, including interest, reasonably expected to be recovered in a subsequent accounting period.

Pursuant to SSAP No. 101, gross DTAs are first reduced by a statutory valuation allowance adjustment to an amount that is more likely than not to be realized ("adjusted gross DTAs"). Adjusted gross DTAs are then admitted in an amount equal to the sum of paragraphs a. b. and c. below:

- a. Federal income taxes paid in prior years that can be recovered through loss carrybacks for existing temporary differences that reverse during a timeframe corresponding with Internal Revenue Code ("IRC") tax loss carryback provisions.
- b. The amount of adjusted gross DTAs, after the application of paragraph a. above, expected to be realized within the applicable period and that is no greater than the applicable percentage as determined using the applicable Realization Threshold Limitation Table. The applicable period refers to the number of years in which the DTA

will reverse in the Company's tax return and the applicable percentage refers to the percentage of the Company's statutory capital and surplus as required to be shown on the statutory balance sheet adjusted to exclude any net DTAs, electronic data processing equipment and operating system software and any net positive goodwill ("Stat Cap ExDTA").

The Realization Threshold Limitation Tables allow DTAs to be admitted based upon either realization within 3 years and 15% of Stat Cap ExDTA, 1 year and 10% of Stat Cap ExDTA, or no DTA admitted pursuant to this paragraph b. In general, the Realization Threshold Limitation Tables allow the Company to admit more DTAs if total DTAs as reported by the Company are a smaller percentage of statutory capital and surplus.

c. The amount of gross DTAs, after the application of paragraphs a. and b. above that can be offset against existing gross DTLs. In applying this offset, the Company considers the character (i.e. ordinary versus capital) of the DTAs and DTLs such that offsetting would be permitted in the tax return under existing enacted federal income tax laws and regulations and the reversal patterns of temporary differences.

Changes in DTAs and DTLs are recognized as a separate component of gains and losses in surplus ("Change in net deferred income tax") except to the extent allocated to changes in unrealized gains and losses. Changes in DTAs and DTLs allocated to unrealized gains and losses are netted against the related changes in unrealized gains and losses and are reported as "Change in net unrealized capital gains (losses)", also a separate component of gains and losses in surplus.

The Company is subject to state income taxes in various states. State income tax expense is recorded in general administrative expenses in the Statutory Statements of Revenue and Expenses. For the years ended December 31, 2022 and 2021, the Company incurred state income tax expense (benefit) of \$255,573 and \$(78,916), respectively.

The Company had \$57,615 and \$158,530 of state income tax receivables at December 31, 2022 and 2021, respectively. These balances were included as aggregate write-ins for other than invested assets in the Statutory Statements of Assets.

#### D. Going Concern

As of February 24, 2023, management evaluated whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern and management has determined that it is not probable that the Company will be unable to meet its obligations as they become due within one year after the financial statements are available to be issued. Management will continuously evaluate the Company's ability to continue as a going concern and will take appropriate action and will make appropriate disclosures if there is any change in any condition or events that would raise substantial doubt about the Company's ability to continue as a going concern.

#### 2. Accounting Changes and Corrections of Errors

The Company did not have any accounting changes or correction of errors in the years ended December 31, 2022 and 2021.

#### 3. Business Combinations and Goodwill

The Company was not a part of any business combinations that involved the statutory purchase method, a statutory merger, an assumption reinsurance, or an impairment loss in the years ending December 31, 2022 and 2021.

### 4. <u>Discontinued Operations</u>

The Company did not have any operations receiving discontinued operations accounting treatment during the years ending December 31, 2022 and 2021.

## 5. <u>Investments</u>

- A. The Company did not have any mortgage loans, including Mezzanine Real Estate Loans, at December 31, 2022 or 2021.
- B. The Company did not have any debt restructuring in the years ending December 31, 2022 or 2021.
- C. The Company did not have any reverse mortgages at December 31, 2022 or 2021.
- D. The Company did not have any loan-backed securities at December 31, 2022 or 2021.
- E. The Company had no dollar repurchase agreements and/or securities lending transactions at December 31, 2022.
- F. The Company did not have any repurchase agreements transactions accounted for as secured borrowing at December 31, 2022.
- G. The Company did not have any reverse repurchase agreements transactions accounted for as secured borrowing at December 31, 2022.
- H. The Company did not have any repurchase agreements transactions accounted for as a sale at December 31, 2022.
- I. The Company did not have any reverse repurchase agreements transactions accounted for as a sale at December 31, 2022.

- J. The Company did not have any real estate at December 31, 2022.
- K. The Company did not have any low-income housing tax credits at December 31, 2022 or 2021.

#### L. Restricted Assets

(1) Restricted assets (including pledged):

	I	I					
	1	2	3	4	5	6	7
Restricted Asset Category	Total Gross (Admitted & Nonadmitted) Restricted from Current Year	Total Gross (Admitted & Nonadmitted) Restricted from Prior Year	Increase/ (Decrease) (1 minus 2)	Total Current Year Nonadmitted Restricted	Total Current Year Admitted Restricted (1 minus 4)	Gross (Admitted & Nonadmitted) Restricted to Total Assets (a)	Admitted Restricted to Total Admitted Assets (b)
a. Subject to contractual obligation for which liability is not shown							_
b. Collateral held under security lending agreements						_	_
c. Subject to repurchase agreements						_	_
d. Subject to reverse repurchase agreements						_	_
e. Subject to dollar repurchase agreements						_	_
f. Subject to dollar reverse repurchase agreements						_	_
g. Placed under option contracts						_	_
h. Letter stock or securities restricted as to sale - excluding FHLB capital stock						_	_
i. FHLB capital stock						_	_
j. On deposit with states	\$ 2,114,889	\$ 1,981,525	\$ 133,364	_	\$ 2,114,889	1.573	1.577
k. On deposit with other regulatory bodies						_	_
Pledged collateral to FHLB (including assets backing funding agreements)						_	_
m. Pledged as collateral not captured in other categories						_	_
n. Other restricted assets						_	_
o. Total Restricted Assets (Sum of a through n)	\$ 2,114,889	\$ 1,981,525	\$ 133,364	\$ —	\$ 2,114,889	1.573	1.577

(a) Column 1 divided by Asset Page, Column 1, Line 28 (b) Column 5 divided by Asset Page, Column 3, Line 28

- (2) The Company did not have any assets pledged as collateral not captured in other categories at December 31, 2022 or 2021.
- (3) The Company did not have any other restricted assets at December 31, 2022 or 2021.
- (4) The Company did not have any collateral received and reflected within its financial statements at December 31, 2022.
- M. The Company did not have any working capital finance investments at December 31, 2022.
- N. The Company did not have any offsetting and netting of derivative, repurchase and reverse repurchase, and securities borrowing and securities lending assets or liabilities at December 31, 2022.
- O. The Company did not have any 5GI securities at December 31, 2022 or 2021.
- P. The Company did not have any short sales at December 31, 2022.
- Q. The Company did not have any prepayment penalty and acceleration fees at December 31, 2022.
- R. The Company did not participate in any qualified cash pools at December 31, 2022.
- 6. Joint Ventures, Partnerships, and Limited Liability Companies
  - A. The Company did not have any joint ventures, partnerships, or limited liability companies that exceeded 10% of its admitted assets at December 31, 2022 or 2021.
  - B. The Company does not have any impaired investments in joint ventures, partnerships, or limited liability companies at December 31, 2022 or 2021.

#### 7. Investment Income

A. Due and accrued income was excluded from surplus on the following bases:

Bonds - where collection of interest is uncertain.

B. There was no amount excluded at December 31, 2022 or 2021.

#### **Derivative Instruments**

The Company did not have any derivative instruments at December 31, 2022 or 2021.

#### Income Taxes

A.

(1) The components of the net DTAs recognized in the Company's Statutory Statements of Assets and Liabilities, Capital and Surplus are as follows:

			12/31/2022			12/31/2021		Change				
		(1) Ordinary	(2) Capital	(3) (Col. 1 + 2) Total	(4) Ordinary	(5) Capital	(6) (Col. 4 + 5) Total	(7) (Col. 1 - 4) Ordinary	(8) (Col. 2 - 5) Capital	(9) (Col. 7 + 8) Total		
(a)	Gross Deferred Tax Assets	\$1,603,339	\$ 20,155	\$1,623,494	\$ 64,068	\$ 4,657	\$ 68,725	\$ 1,539,271	\$ 15,498	\$ 1,554,769		
(b)	Statutory Valuation Allowance Adjustment	_	11,163	11,163	_	_	_	_	11,163	11,163		
(c)	Adjusted Gross Deferred Tax Assets (1a - 1b)	1,603,339	8,992	1,612,331	64,068	4,657	68,725	1,539,271	4,335	1,543,606		
(d)	Deferred Tax Assets Nonadmitted	_	_	_	_	4,113	4,113	_	(4,113)	(4,113)		
(e)	Subtotal Net Admitted Deferred Tax Asset (1c - 1d)	1,603,339	8,992	1,612,331	64,068	544	64,612	1,539,271	8,448	1,547,719		
(f)	Deferred Tax Liabilities	35,572	8,993	44,565	13,163	544	13,707	22,409	8,449	30,858		
(g)	Net Admitted Deferred Tax Asset/(Net Deferred Tax Liability) (1e - 1f)	\$1,567,767	\$ (1)	\$1,567,766	\$ 50,905	\$ —	\$ 50,905	\$ 1,516,862	\$ (1)	\$ 1,516,861		

(2) The amount of admitted gross DTAs admitted under each component of SSAP No. 101:

		12/31/2022				12/31/2021		Change				
		(1) Ordinary	(2) Capital	(3) (Col. 1 + 2) Total	(4) Ordinary	(5) Capital	(6) (Col. 4 + 5) Total	(7) (Col. 1 - 4) Ordinary	(8) (Col. 2 - 5) Capital	(9) (Col. 7 + 8) Total		
Admission Calculation Components SSAP No. 101		Orumary	Сарнаі	Total	Orumary	Сарнаі	Total	Ordinary	Сарісаі	Total		
(a)	Federal Income Taxes Paid In Prior Years Recoverable Through Loss Carrybacks.	\$1,601,787	\$ —	\$1,601,787	\$ 61,555	s —	\$ 61,555	\$ 1,540,232	s —	\$ 1,540,232		
(b)	Adjusted Gross Deferred Tax Assets Expected To Be Realized (Excluding The Amount Of Deferred Tax Assets From 2(a) above) After Application of the Threshold Limitation. (The Lesser of 2(b)1 and 2(b)2 Below)	1,552	_	1,552	2,513		2,513	(961)	_	(961)		
	Adjusted Gross Deferred     Tax Assets Expected to be     Realized Following the     Balance Sheet Date.	1,552		1,552	2,513	_	2,513	(961)	_	(961)		
	2. Adjusted Gross Deferred Tax Assets Allowed per Limitation Threshold.	XX	XX	6,364,584	XX	XX	3,154,417	XX	XX	3,210,167		
(c)	Adjusted Gross Deferred Tax Assets (Excluding The Amount Of Deferred Tax Assets From 2(a) and 2(b) above) Offset by Gross Deferred Tax Liabilities.	_	8,992	8,992	_	544	544	_	8,448	8,448		
	Deferred Tax Assets Admitted as the result of application of SSAP No. 101. Total $(2(a) + 2(b) + 2(c))$											
(d)		\$1,603,339	\$ 8,992	\$1,612,331	\$ 64,068	\$ 544	\$ 64,612	\$ 1,539,271	\$ 8,448	\$ 1,547,719		

(3)

303 % Ratio Percentage Used To Determine Recovery Period And Threshold Limitation Amount.

Amount Of Adjusted Capital And Surplus Used To Determine Recovery Period And Threshold Limitation In 2(b)2 Above. \$ 42,430,563 \$ 21,029,445

(4) The impact of tax planning strategies is as follows:

	12/31	/2022	12/31	/2021	Cha	inge
	(1)	(2)	(3)	(4)	(5) (Col. 1 - 3)	(6) (Col. 2 - 4)
	Ordinary	Capital	Ordinary Capital		Ordinary	Capital
Impact of Tax Planning Strategies:						
(a) Determination of adjusted gross deferred tax assets and net admitted deferred tax assets, by tax character as a percentage.						
1. Adjusted Gross DTAs amount from Note 9A1(c)	\$ 1,603,339	\$ 8,992	\$ 64,068	\$ 4,657	\$ 1,539,271	\$ 4,335
<ol><li>Percentage of adjusted gross DTAs by tax character attributable to the impact of tax planning strategies</li></ol>	— %	— %	— %	— %	— %	— %
3. Net Admitted Adjusted Gross DTAs amount from Note 9A1(e)	1,603,339	8,992	64,068	544	1,539,271	8,448
4. Percentage of net admitted adjusted gross DTAs by tax character admitted because of the impact of tax planning	— %	— %	— %	— %	<b></b> %	— %

<sup>(</sup>b) Do the Company's tax-planning strategies include the use of reinsurance?

Yes [ ] No [X]

B. There are no DTLs that were not recognized at December 31, 2022 or 2021.

C. Current income taxes incurred consist of the following major components:

				(1)	(2)	(3)
	~					(Col. 1 - 2)
1.		rent Income Tax	_	12/31/2022	12/31/2021	Change
	(a)	Federal	\$	1,610,548	\$ (495,908)	2,106,456
	(b)	Foreign		1 610 549	(405,009)	2,106,456
	(c) (d)	Subtotal (1a+1b) Federal income tax on net capital gains		1,610,548 13	(495,908) 314	(301)
	(u) (e)	Utilization of capital loss carry-forwards		13	314	(301)
	(f)	Other				
	(g)	Federal and foreign income taxes incurred (1c+1d+1e+1f)		1,610,561	(495,594)	2,106,155
2.	Dof	erred Tax Assets:				
۷.	(a)	Ordinary:				
	(u)	(1) Discounting of unpaid losses		155,220	50,262	104,958
		(2) Unearned premium reserve		1,085	760	325
		(3) Policyholder reserves		1,371,950	_	1,371,950
		(4) Investments			_	
		(5) Deferred acquisition costs		_	_	_
		(6) Policyholder dividends accrual		_	_	_
		(7) Fixed assets		_	_	_
		(8) Compensation and benefits accrual		_	_	_
		(9) Pension accrual		_	_	_
		(10) Receivables - nonadmitted		75,084	13,046	62,038
		(11) Net operating loss carry-forward		_	_	_
		(12) Tax credit carry-forward		_	_	_
		(13) Other		_	_	_
		(99) Subtotal (sum of 2a1 through 2a13)		1,603,339	64,068	1,539,271
	(b)	Statutory valuation allowance adjustment		_	_	_
	(c)	Nonadmitted		_	_	_
	(d)	Admitted ordinary deferred tax assets (2a99 - 2b - 2c)		1,603,339	64,068	1,539,271
	(e)	Capital:				
		(1) Investments		20,155	4,657	15,498
		(2) Net capital loss carry-forward		_	_	_
		(3) Real estate		_	_	_
		(4) Other		_	_	_
		(99) Subtotal (2e1+2e2+2e3+2e4)		20,155	4,657	15,498
	(f)	Statutory valuation allowance adjustment		11,163		11,163
	(g)	Nonadmitted			4,113	(4,113)
	(h)	Admitted capital deferred tax assets (2e99 - 2f - 2g)		8,992	544	8,448
	(i)	Admitted deferred tax assets (2d + 2h)		1,612,331	64,612	1,547,719
3.	Defe	erred Tax Liabilities:				
	(a)	Ordinary:				
		(1) Investments		_	117	(117)
		(2) Fixed assets		_	_	_
		(3) Deferred and uncollected premium		_	_	_
		(4) Policyholder reserves		_	_	_
		(5) Other		35,572	13,046	22,526
	<i>a</i> :	(99) Subtotal (3a1+3a2+3a3+3a4+3a5)		35,572	13,163	22,409
	(b)	Capital:		2.22		
		(1) Investments		8,993	544	8,449
		(2) Real estate		_		-
		(3) Other (20) School (2) (2) (2) (2) (2)		- 0.002		0.440
	(c)	(99) Subtotal (3b1+3b2+3b3)  Deferred toy liabilities (2c00 + 2b00)		8,993	544	8,449
4.	(c)	Deferred tax liabilities (3a99 + 3b99) deferred tax assets/liabilities (2i - 3c)	\$	44,565 1,567,766	\$ 13,707 \$ 50,905	30,858 1,516,861
→.	1101	deferred tax assets/fidulifities (21 - 30)	\$	1,307,700	φ 50,905	1,510,001

The change in net deferred income taxes is comprised of the following:

	 12/31/2022	12/31/2021	Change
Total Deferred Tax Assets	\$ 1,612,331 \$	68,725 \$	1,543,606
Total Deferred Tax Liabilities	 (44,565)	(13,707)	(30,858)
Net Deferred Tax Assets/(Liabilities)	1,567,766	55,018	1,512,748
Tax Effect of Unrealized Gains/(Losses)			(15,499)
Change in Net Deferred Income Tax		\$	1,497,249

The valuation allowance adjustment to gross DTAs was \$11,163 as of Deceber 31, 2022. There was no valuation allowance adjustment to gross DTAs as of December 31, 2021.

D. The provision for federal income taxes is different from that which would be obtained by applying the statutory federal income tax rate to income before income taxes. The items causing this difference were as follows:

	1	2/31/2022	Effective Tax Rate	12/31/2021	Effective Tax Rate
Provision computed at statutory rate	\$	709,990	21.0 %	\$ (358,263)	21.0 %
Transfer pricing adjustment		(544,703)	(16.1)%	(170,469)	10.0 %
Change in nonadmitted assets		(62,038)	(1.8)%	(12,125)	0.7 %
Prior year true-up		(1,100)	0.0 %	(45)	0.0 %
Change in valuation allowance adjustment		11,163	0.3 %		0.0 %
Total	\$	113,312	3.4 %	\$ (540,902)	31.7 %
Federal and foreign income taxes incurred	\$	1,610,561	47.6 %	\$ (495,594)	29.0 %
Change in net deferred income taxes		(1,497,249)	(44.2)%	(45,308)	2.7 %
Total statutory income taxes	\$	113,312	3.4 %	\$ (540,902)	31.7 %

The transfer pricing adjustment allows taxpayers to apply different methods to price current period intercompany services at arm's length prices (i.e., prices at which unrelated entities would be willing to transact), which results in a permanent deduction for tax reporting purposes.

E.

- (1) At December 31, 2022 and 2021, the Company had no net capital loss or net operating loss carryforwards for tax purposes.
- (2) The amount of federal income taxes incurred that is available for recoupment in the event of future net losses is as follows:

Year	Ordinary		Ordinary Capital		Total
2022	\$	1,611,648 \$	13	\$	1,611,661
2021		_	314		314
2020		N/A	_		_
Total	\$	1,611,648 \$	327	\$	1,611,975

(3) The Company did not report any deposits as admitted assets under Internal Revenue Code Section 6603 at December 31, 2022 and 2021.

F.

(1) At December 31, 2022, the Company's Federal Income Tax Return was consolidated with the following entities:

CVS HEALTH CORPORATION Mental Health Network of New York IPA, Inc.

CVS PHARMACY INC. Meritain Health, Inc.

ACCENDO INSURANCE COMPANY Niagara Re, Inc.

BRUIN ACQUISITION CO., INC. Performax, Inc.

CORAM ALTERNATE SITE SERVICES, INC. Precision Benefit Services, Inc.

Apria Finance Holdings, Inc. PrimeNet, Inc.

CORAM HEALTHCARE CORPORATION OF GREATER D.C. Professional Risk Management, Inc.

CORAM HEALTHCARE CORPORATION OF FLORIDA Resources for Living, LLC

Coram Healthcare Corporation of Indiana Schaller Anderson Medical Administrators Inc

Coram Healthcare Corporation of Massachusetts

The Vasquez Group, Inc.

Coram Healthcare Corporation of Mississippi

U.S. Healthcare Properties, Inc.

Coram Healthcare Corporation of Northern California

Work & Family Benefits, Inc.

Coram Healthcare Corporation of North Texas

Aetna Better Health, Inc. (Connecticut)

Coram Healthcare Corporation of Nevada

Aetna Better Health Inc. (Georgia)

Coram Healthcare Corporation of Greater New York

Aetna Better Health Premier Plan MMAI Inc.

Coram Healthcare Corporation of Southern California

Aetna Better Health, Inc. (LA)

CORAM HEALTHCARE CORPORATION OF SOUTHERN FLORIDA Actna Better Health Inc. (NJ)

Coram Healthcare Corporation of Utah Actna Better Health Inc. (NY)

SKY ACQUISITION LLC Actna Better Health Inc. (OH)

T2 Medical, Inc.

Aetna Better Health, Inc. (PA)

ALABAMA CVS PHARMACY, L.L.C.

Aetna Better Health of Tennessee Inc.

CVS ARCLIGHT, INC.

Aetna Better Health of California, Inc.

CONNECTICUT CVS PHARMACY, L.L.C. Aetna Health of Ohio, Inc.

DELAWARE CVS PHARMACY, L.L.C.

HOLIDAY CVS, L.L.C.

IOWA CVS PHARMACY, L.L.C. CVS INTERNATIONAL, L.L.C. KENTUCKY CVS PHARMACY, L.L.C. MASSACHUSETTS CVS PHARMACY, INC. MARYLAND CVS PHARMACY, L.L.C. NORTH CAROLINA CVS PHARMACY, L.L.C. OKLAHOMA CVS PHARMACY, L.L.C.

CVS PR Center, Inc.

TENNESSEE CVS PHARMACY, L.L.C.

VIRGINIA CVS PHARMACY, L.L.C. ECKERD CORPORATION OF FL, INC.

E.T.B., INC. CVS WWRE, INC. CVS RX SERVICES, INC. MELVILLE REALTY CO., INC.

MINUTECLINIC DIAGNOSTIC OF ILLINOIS, LLC

ACS Acqco Corp.

Advanced Care Scripts, Inc.

CVS CAREMARK INDEMNITY LTD.

CVS FOREIGN, INC.

RICHMOND HEIGHTS ACQUISITION CORP.

SILVERSCRIPT INSURANCE COMPANY

RETRAC, INC. UAC HOLDING, INC.

CAREMARK ULYSSES HOLDING CORP.

@ Credentials Inc.

Active Health Management, Inc.

ADMINCO, Inc.

Administrative Enterprises, Inc. CVS Accountable Care Organization Inc.

Aetna Ireland Inc.

Aetna Student Health Agency, Inc. American Health Holding, Inc. AUSHC Holdings, Inc. (CT) Carefree Insurance Services, Inc.

Claims Administration Corporation

Cofinity, Inc.

Coventry Consumer Advantage, Inc.

Coventry Health Care National Accounts, Inc. Coventry Health Care National Network, Inc.

Coventry HealthCare Management Corporation Coventry Prescription Management Services, Inc.

Coventry Transplant Network, Inc.

Echo Merger Sub, Inc

First Health Group Corp.

Florida Health Plan Administrators, LLC

Group Dental Service, Inc.

Health and Human Resource Center, Inc. Health Data & Management Solutions, Inc.

Managed Care Coordinators, Inc. Mental Health Associates, Inc.

Aetna Better Health of Kentucky Insurance Co.

Aetna Better Health of Kansas Inc. Aetna Better Health of Michigan, Inc. Aetna Better Health of Missouri LLC Aetna Better Health of Nevada Inc. Aetna Better Health of Oklahoma Inc. Aetna Better Health of Texas, Inc. Aetna Dental Inc. (New Jersey) Aetna Dental Inc. (Texas) Aetna Dental of California, Inc.

Aetna Florida, Inc.

Aetna Health Inc. (Connecticut) Aetna Health Inc. (Florida) Aetna Health Inc. (Georgia) Aetna Health Inc. (LA) Aetna Health Inc. (Maine) Aetna Health of Michigan Inc. Aetna Health Inc. (New Jersey)

Aetna Health Inc. (NY)

Aetna Health Inc. (Pennsylvania) Aetna Health Inc. (Texas) Aetna Health Insurance Co

Aetna Health Insurance Company of New York

Aetna Health of California Inc. Aetna Health of Iowa, Inc Aetna Health of Utah, Inc. HealthAssurance Pennsylvania, Inc.

Aetna Risk Assurance Company of Connecticut Coventry Health and Life Insurance Company

Aetna Better Health of Florida, Inc. Coventry Health Care of Illinois, Inc. Coventry Health Care of Kansas, Inc. Coventry Health Care of Missouri, Inc. Coventry Health Care of Nebraska, Inc. Coventry Health Care of Virginia, Inc. Coventry Health Care of West Virginia, Inc. Coventry Health Plan of Florida, Inc.

First Health Life and Health Insurance Company

Group Dental Service of Maryland, Inc.

Delaware Physicians Care, Inc.

Health Re, Inc.

Aetna Better Health of Washington, Inc. Aetna Better Health of North Carolina, Inc.

CVS AOC Corporation

MinuteClinic Physician Practice of Texas

MinuteClinic Telehealth Services of Texas Associatio

Aetna Corporate Services LLC

Aetna Better Health of Illinois Inc. (fka IlliniCare Health Plan, Inc.)

Aetna Health and Life Insurance Company

First Choice of the Midwest Inc. Aetna Better Health of Indiana Inc. Zinc Health Ventures LLC

Aetna HealthAssurance Pennsylvania, Inc.

MHNet of Florida, Inc.

(2) As explained in Note 1, the Company participates in a tax sharing agreement with its parent and affiliates.

- G. The Company does not have any tax loss contingencies for which it is reasonably possible that the total liability will significantly increase within twelve months of the reporting date.
- H. The Company was not subject to the Repatriation Transition Tax at December 31, 2022 and 2021.
- The Company did not recognize any gross Alternative Minimum Tax credit at December 31, 2022 and 2021.

On August 16, 2022, President Biden signed into law the Inflation Reduction Act (the "Act"). Effective for tax years beginning after December 31, 2022, the Act includes a new corporate alternative minimum tax ("CAMT") on certain corporations. The aggregate group of which the Company is a member has not determined as of the reporting date if it will be liable for CAMT in 2023. The financial statements as of December 31, 2022 do not include an estimated impact of the CAMT because a reasonable estimate cannot be made.

10. Information Concerning Parent, Subsidiaries, Affiliates, and Other Related Parties

#### A. and B.:

Transactions occurring between the Company and its parent, subsidiaries and affiliates excluding reinsurance transactions and non-insurance transactions involving less than ½ of 1% of the Company's total admitted assets and cost allocation transactions follow:

December 31, 2022

				Assets received by insurer Assets tra		Assets received by insurer		rred by insurer
Date of transaction	Explanation of transaction	Name of reporting entity	Name of affiliate		Statement value	Statement description	Statement value	Statement description
December 29, 2022	Capital Contribution	Aetna Health of Michigan Inc.	Aetna Health Holdings, LLC	\$	20,000,000	Cash		

December 31, 2021

				Assets received by insurer		Assets transfe	rred by insurer
Date of transaction	Explanation of transaction	Name of reporting entity	Name of affiliate	Statement value	Statement description	Statement value	Statement description
December 31, 2021	Capital Contribution	Aetna Health of Michigan Inc.	Aetna Health Holdings, LLC	\$ 10,000,000	Cash		

- C. The Company did not have any transactions with related parties who are not reported on Schedule Y at December 31, 2022.
- D. At December 31, 2022 and 2021, the Company had the following amounts due to and due from affiliates, which exclude amounts related to pharmacy rebate transactions as discussed more fully in Note 28 and the Company's reinsurance agreements if applicable.

		December 31,					
		2021					
Amounts due to affiliates							
Aetna Health Management, LLC	\$	14,722,627 \$	3,878,580				
Total due to affiliates	\$	14,722,627 \$	3,878,580				
		December 31,					
		2022	2021				
Amounts due from affiliates							
Aetna Health Holdings, LLC	\$	— \$	10,000,000				
Total due from affiliates	\$	<b>—</b> \$	10,000,000				

The terms of settlement require that these amounts be settled within 45 days after the end of the calendar quarter.

E. As of and for the years ended December 31, 2022 and 2021, the Company had the following significant transactions with affiliates:

The Company and Aetna Health Management, LLC ("AHM") are parties to an administrative services agreement, under which AHM provides certain administrative services, which include but are not limited to, accounting and processing of premiums and claims. Under this agreement, the Company remits a percentage of its earned Medicare premium revenue, as applicable, to AHM as a fee, subject to an annual true up mechanism as defined in the agreement. Under the agreement, this true-up is due to be settled with the affiliate by April 15th of the following contract year (which is January 1 to December 31 annually). The terms of settlement require that these amounts be settled within 45 days after the end of the calendar quarter. For these services, the Company was charged \$47,887,712 and \$14,515,733 in 2022 and 2021, respectively.

The agreement with AHM also enables the Company to receive manufacturers' pharmacy rebates from Caremark-PCS Health, LLC, an affiliate, to deliver pharmacy benefit management services to the Company via AHM. The Company earned pharmaceutical rebates of \$39,749,287 and \$10,241,182, which were recorded as a reduction of medical costs, in 2022 and 2021, respectively.

These agreements also provide for interest on all intercompany balances. Interest earned on amounts due from affiliates was \$153,403 in 2022 and \$2,354 in 2021. Interest incurred on amounts due to affiliates was \$57,437 in 2022 and \$2,409 in 2021.

The Company has an insolvency agreement with Aetna Health Insurance Company ("AHIC"), a wholly-owned subsidiary of CVS Health. This agreement provides that in the event that the Company ceases operations or becomes insolvent, AHIC will continue to pay benefits for any members confined as inpatients on the date of insolvency until their discharge. This agreement also provides that AHIC will continue benefits for any member until the end of the contract period for which premium has been paid, but for no longer than thirty-one days. AHIC will also make available to members, for a period of thirty-one days, replacement insurance policies.

As explained in Note 1, Aetna and its wholly-owned subsidiaries, including the Company, participate in a tax sharing agreement with CVS Health. All federal income tax receivables/payables are due from/due to CVS Health.

- F. The Company does not have any guarantees or undertakings, written or otherwise, at December 31, 2022.
- G. All outstanding shares of the Company are owned by Aetna Health Holdings, LLC, whose ultimate parent is CVS Health.
- H. At December 31, 2022, the Company did not own shares of an upstream intermediate entity or CVS Health, either directly or indirectly.
- I. At December 31, 2022, the Company did not hold any investments in any subsidiary, controlled or affiliated ("SCA") entity that exceeded 10% of the Company's admitted assets.
- J. At December 31, 2022, the Company did not hold any investments in any impaired SCA entity.
- K. At December 31, 2022, the Company did not hold any investments in any foreign insurance subsidiaries.
- L. At December 31, 2022, the Company did not hold any investments in a downstream noninsurance holding company.
- M. At December 31, 2022, the Company did not have any SCA investments.
- N. At December 31, 2022, the Company did not have any investments in an insurance SCA.
- O. The Company did not have any SCA or SSAP No. 48 entity investments where the Company's share of losses in the SCA exceeds its investment in the SCA.

### 11. <u>Debt</u>

- A. The Company did not have any items related to debt, including capital notes at December 31, 2022.
- B. The Company did not have any Federal Home Loan Bank agreements at December 31, 2022.
- 12. <u>Retirement Plans, Deferred Compensation, Postemployment Benefits and Compensated Absences and Other Postretirement Benefit Plans</u>
  - A.- I. The Company did not have a retirement plan, deferred compensation plan, or other postretirement benefit plan at December 31, 2022 or 2021.
- 13. Capital and Surplus, Dividend Restrictions and Quasi-Reorganizations
  - A. The Company had 4,000 shares of common stock and 1,000 shares of class B stock, with a par value of \$0.01 per share authorized, with 1,000 shares issued and outstanding at December 31, 2022 and 2021.
  - B. The Company had 50 shares of preferred stock with a par value of \$0.01 authorized and no shares issued and outstanding at December 31, 2022 and 2021.
  - C. Dividend Restrictions

Shareholder dividends shall be declared or paid only from earned surplus, unless the Michigan Department approves the dividend prior to payment. Dividends not requiring prior approval are limited to the greater of 10% of the insured's surplus as regards policyholders as of December 31 of the immediately preceding year, or the net income, not including realized capital gains, for the 12 month period ending December of the immediately preceding year. Ordinary dividends are ultimately limited to earned surplus.

- D. The Company did not pay any dividends in 2022 or 2021.
- E. Within the limitations of (C) above, there are no other restrictions placed on the portion of the Company profits that may be paid as ordinary dividends to stockholders.
- F. There were no restrictions placed on the Company's surplus, including for whom the surplus is being held.
- G. The Company had no advances to surplus not repaid.
- H. The Company did not hold any stock for any special purposes at December 31, 2022 or 2021.
- I. There were no changes in the balances of special surplus funds from the prior year.
- J. At December 31, 2022, there was \$58,306 of unassigned funds that was represented or reduced by unrealized gains and losses.
- K. The Company has not issued any surplus notes or debentures or similar obligations at December 31, 2022 or 2021.
- L. The Company did not participate in any quasi-reorganizations during the statement year.

M. The Company did not participate in any quasi-reorganizations in the past 10 years.

### 14. <u>Liabilities, Contingencies and Assessments</u>

A. The Company did not have any contingent commitments at December 31, 2022 or 2021.

#### B. Assessments

### **Guaranty Fund Assessments**

(1) Under guaranty fund laws existing in all states, insurers doing business in those states can be assessed (in most states up to prescribed limits) for certain obligations of insolvent insurance companies to policyholders and claimants. The life and health insurance guaranty associations in which the Company participates that operate under these laws respond to insolvencies of long-term care insurers and life insurers as well as health insurers. The Company's assessments generally are based on a formula relating to the Company's health care premiums in the state compared to the premiums of other insurers. Certain states allow assessments to be recovered over time as offsets to premium taxes. Some states have similar laws relating to HMOs and/or other payers such as not-for-profit consumer-governed health plans established under the ACA.

The Company did not have any contingent assessments at December 31, 2022 or 2021.

- C. The Company did not have any gain contingencies at December 31, 2022 or 2021.
- D. The Company did not have any claims related extra contractual obligation and bad faith losses stemming from lawsuits at December 31, 2022 or 2021.
- E. The Company did not have any joint and several liability arrangements at December 31, 2022 or 2021.
- F. Various liabilities arise in the normal course of the Company's business and have been recorded. In the opinion of management, any ultimate contingent losses will not have a material adverse effect on the Company's future results of operations and financial position. The Company, to the best of its knowledge, has no assets that it considers impaired that are not already recorded in the Company's books.

The Company maintains insurance coverage for certain litigation exposures in an amount it believes is reasonable.

### 15. Leases

The Company did not have any material lease obligations at December 31, 2022 or 2021.

16. <u>Information about Financial Instruments with Off-Balance Sheet Risk and Financial Instruments with Concentrations of Credit Risk</u>

The Company did not have any financial instruments with off-balance sheet risk or financial instruments with concentrations of credit risk at December 31, 2022 or 2021.

- 17. Sale, Transfer and Servicing of Financial Assets and Extinguishments of Liabilities
  - A. Transfers of Receivables Reported as Sales

The Company did not have any transfers of receivables reported as sales for the years ending December 31, 2022 or 2021.

- B. Transfer and Servicing of Financial Assets
  - (1) The Company did not have any loaned securities at December 31, 2022 or 2021.
  - (2) and (3):

The Company did not have any servicing assets or liabilities at December 31, 2022 or 2021.

- (4) The Company did not have any securitized financial assets at December 31, 2022 or 2021.
- (5) The Company did not have any transfers of financial assets accounted for as secured borrowing at December 31, 2022 or 2021.
- (6) The Company did not have any transfers of receivables with recourse at December 31, 2022 or 2021.
- (7) The Company did not have any dollar repurchase or reverse repurchase agreements at December 31, 2022 or 2021.

### C. Wash Sales

(1) In the course of the Company's asset management, securities are sold and reacquired within 30 days of the sale date to enhance the Company's yield on its investment portfolio.

- (2) The Company had no securities sold during the year for the year ended December 31, 2022 and reacquired within 30 days of the sale date.
- 18. Gain or Loss to the Reporting Entity from Uninsured Plans and the Uninsured Portion of Partially Insured Plans
  - A. The Company did not serve as an Administrative Services Only ("ASO") plan administrator for uninsured accident and health plans or the uninsured portion of partially insured plans for the period ended December 31, 2022.
  - B. The Company did not serve as an Administrative Services Contract plan administrator for uninsured accident and health plans or the uninsured portion of partially insured plans for the period ended December 31, 2022.
  - C. Medicare or Similarly Structured Cost Based Reimbursement Contract:
    - (1) Revenue from the Company's Medicare (or similarly structured cost based reimbursement contract) contract for the year 2022 was \$399,594,562.
    - (2) As of December 31, 2022, the Company has recorded receivables from the following payors whose account balances are greater than 10% of the Company's amounts receivable from uninsured accident and health plans or \$10,000:

Centers for Medicare and Medicaid Services \$52,315

- (3) In connection with the Company's Medicare (or similarly structured cost based reimbursement contract) contract, the Company has recorded allowance and reserves for adjustment of recorded revenues as and if applicable.
- (4) CMS periodically perform audits of Medicare revenue and may seek return of premium payments made to the Company if risk adjustment factors are not properly supported by medical record data. The Company estimates and records reserves for CMS audits based on information available at the time the estimates are made. Although the Company believes it maintains appropriate reserves for its exposure to the CMS audits, actual results could differ materially from those estimates.
- 19. <u>Direct Premium Written/Produced by Managing General Agents/Third Party Administrators</u>

The Company did not have any material direct premiums written through/produced by managing general agents or third party administrators for the years ended December 31, 2022 and 2021.

### 20. Fair Value Measurements

A.

- (1) The Company had no material assets and liabilities that are measured and reported at fair value in the financial statements as of December 31, 2022 or 2021.
- (2) There were no material realized and unrealized capital gains, purchases, sales, settlements, or transfers into or out of the Company's Level 3 financial assets during 2022 or 2021.
- (3) Transfers in and out of all levels are recognized at the end of the reporting period of which the transfer occurred.
- (4) The Company's fair value measurement valuation techniques are described in B. below.
- (5) The Company did not have any derivative instruments at December 31, 2022 or 2021.
- B. The fair values of the Company's financial instruments are based on valuations that include inputs that can be classified within one of three levels of a hierarchy. The following are the levels of the hierarchy and a brief description of the type of valuation information ("inputs") that qualifies a financial asset or liability for each level:
  - Level 1 Unadjusted quoted prices for identical assets or liabilities in active markets.
  - Level 2 Inputs other than Level 1 that are based on observable market data. These include: quoted prices for similar assets in active markets, quoted prices for identical assets in inactive markets, inputs that are observable that are not prices (such as interest rates and credit risks) and inputs that are derived from or corroborated by observable markets.
  - Level 3 Developed from unobservable data, reflecting the Company's own assumptions.

Financial assets and liabilities are classified based upon the lowest level of input that is significant to the valuation. When quoted prices in active markets for identical assets and liabilities are available, the Company uses these quoted market prices to determine the fair value of financial assets and liabilities and classifies these assets and liabilities as Level 1. In other cases where a quoted market price for identical assets and liabilities in an active market is either not available or not observable, the Company estimates fair value using valuation methodologies based on available and observable market information or by using a matrix pricing model. These financial assets and liabilities would then be classified as Level 2. If quoted market prices are not available, the Company determines fair value using broker quotes or an internal analysis of each investment's financial performance and cash flow projections. Thus, financial assets and liabilities may be classified in Level 3 even though there may be some significant inputs that may be observable.

C. The carrying values and estimated fair values of the Company's financial instruments at December 31, 2022 and 2021 were as follows:

December 31, 2022

Type of Financial Instrument	Aggregate Fair Value	Admitted Assets	(Level 1)	(Level 2)	(Level 3)	Net Asset Value (NAV)	Not Practicable (Carrying Value)
Bonds, short-term investments and cash equivalents	\$112,847,747	\$114,005,557	\$ 1,913,375	\$110,934,372	s —	s —	\$ —
Common stocks	1,166,217	1,166,217	1,166,217	_	_	_	_

### December 31, 2021

Type of Financial Instrument	Aggregate Fair Value	Admitted Assets	(Level 1)	(Level 2)	(Level 3)	Net Asset Value (NAV)	Not Practicable (Carrying Value)
Bonds, short-term investments and cash equivalents	\$ 26,833,446	\$ 26,833,737	\$ 2,005,516	\$ 24,827,930	\$ —	\$ —	\$

In evaluating the Company's management of interest rate and liquidity risk and currency exposures, the fair values of all assets and liabilities should be taken into consideration, not only those presented above.

- D. The Company did not have any financial instruments where it was not practicable to estimate the fair value.
- E. The Company has not elected to use the net asset value practical expedient to fair value to measure its investments.

### 21. Other Items

### A. <u>Unusual or Infrequent Items</u>

The Company did not have any unusual or infrequent items for the years ended December 31, 2022 and 2021.

### B. Troubled Debt Restructuring

The Company did not have any troubled debt restructuring in the years ended December 31, 2022 and 2021.

### C. Other Disclosures

### Minimum Capital and Surplus

Pursuant to the laws of the states in which the Company is licensed to do business, the Company is required to maintain a minimum surplus and capital stock as defined by the statutes and regulations of those states. At both December 31, 2022 and 2021, the Company was in compliance with the minimum surplus and capital stock requirements of the states in which it is licensed to do business.

The NAIC utilizes risk-based capital ("RBC") standards for health organizations, including HMOs, that are designed to identify weakly capitalized companies by comparing each company's adjusted capital and surplus to its required capital and surplus (the "RBC Ratio"). The RBC Ratio is designed to reflect the risk profile of a company. Within certain ratio ranges, regulators have increasing authority to take action as the RBC Ratio decreases. There are four levels of regulatory action, ranging from requiring insurers to submit a comprehensive plan to the state insurance commissioner to requiring the state insurance commissioner to place the insurer under regulatory control. At December 31, 2022 and 2021, the Company had capital and surplus that exceeded the level that would require regulatory action.

### COVID-19

The Coronavirus Disease 2019 ("COVID-19") pandemic continues to evolve, and the Biden administration has indicated that they intend for the COVID-19 public health emergency to expire on May 11, 2023. The Company believes COVID-19's impact on the Company's businesses, operating results, cash flows and/or financial condition primarily will be driven by the geographies impacted and the severity and duration of the pandemic; the pandemic's impact on the U.S. and global economies and consumer behavior and health care utilization patterns; and the timing, scope and impact of legislation as well as other federal, state and local governmental responses to the pandemic. Those primary drivers are beyond the Company's knowledge and control. As a result, the impact COVID-19 will have on the Company's businesses, operating results, cash flows and/or financial condition is uncertain, but the impact could be adverse and material. COVID-19 also may result in legal and regulatory proceedings, investigations and claims against the Company.

### Health Care Reform

The Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010's (collectively, the "ACA") made broad-based changes to the United States health care system. In June 2021, the United States Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety and issued an opinion preserving the ACA and its consumer protections in its current form. Even though the ACA was deemed constitutional, there may nevertheless be continued efforts to invalidate, modify, repeal or replace portions of it. In addition to

litigation, parts of the ACA continue to evolve through the promulgation of executive orders, legislation, regulations and guidance at the federal or state level. The Company expects the ACA, including potential changes thereto, to continue to significantly impact its business operations and operating results, including pricing, medical benefit ratios ("MBRs") and the geographies in which the Company's products are available.

### Medicare

The Company's Medicare Advantage products are heavily regulated by CMS. The regulations and contractual requirements applicable to the Company and other private participants in Medicare programs are complex, expensive to comply with and subject to change. For example, in the second quarter of 2014, CMS issued a final rule implementing the ACA requirements that Medicare Advantage plans report and refund to CMS overpayments that those plans receive from CMS. The precise interpretation, impact and legality of this rule are not clear and are subject to pending litigation. Payments the Company receives from CMS for its Medicare Advantage business also are subject to risk adjustment based on the health status of the individuals enrolled. Elements of that risk adjustment mechanism continue to be challenged by the U.S. Department of Justice, the Office of Inspector General of the HHS (the "OIG") and CMS itself. Substantial changes in the risk adjustment mechanism, including changes that result from enforcement or audit actions, could materially affect the amount of the Company's Medicare reimbursement, require the Company to raise prices or reduce the benefits offered to Medicare beneficiaries, and potentially limit the Company's (and the industry's) participation in the Medicare program.

The Company has invested significant resources to comply with Medicare standards, and its Medicare compliance efforts will continue to require significant resources. CMS may seek premium and other refunds, prohibit the Company from continuing to market and/or enroll members in or refuse to passively enroll members in one or more of the Company's Medicare or Medicare-Medicaid demonstration (historically known as "dual eligible") plans, exclude the Company from participating in one or more Medicare, dual eligible or dual eligible special needs plan programs and/or institute other sanctions and/or civil monetary penalties against the Company if it fails to comply with CMS regulations or its Medicare contractual requirements.

- D. The Company did not have any business interruption insurance recoveries for the years ending December 31, 2022 or 2021.
- E. The Company did not have any state transferable and non-transferable tax credits for the years ending December 31, 2022 or 2021
- F. The Company did not have any subprime mortgage related risk exposures at December 31, 2022 or 2021.
- G. The Company did not have any retained assets at December 31, 2022 or 2021.
- H. The Company did not have any insurance-linked securities contracts at December 31, 2022 or 2021.
- I. The Company did not have amounts that could be realized on life insurance at December 31, 2022 or 2021.

### 22. Events Subsequent

### Type I - Recognized Subsequent Events

Subsequent events have been considered through February 24, 2023 for the statutory statement issued on February 24, 2023.

The Company had no known reportable recognized subsequent events.

### Type II - Nonrecognized Subsequent Events

Subsequent events have been considered through February 24, 2023 for the statutory statement issued on February 24, 2023.

The Company had no known reportable nonrecognized subsequent events.

### 23. Reinsurance

### A. Ceded Reinsurance Report

### Section 1 – General Interrogatories

(1) Are any of the reinsurers, listed in Schedule S as non-affiliated, owned in excess of 10% or controlled, either directly or indirectly, by the company or by any representative, officer, trustee, or director of the company?

Yes() No(X)

If yes, give full details. N/A

(2) Have any policies issued by the company been reinsured with a company chartered in a country other than the United States (excluding U.S. branches of such companies) that is owned in excess of 10% or controlled directly or indirectly by an insured, a beneficiary, a creditor or an insured or any other person not primarily engaged in the insurance business?

Yes() No (X)

If yes, give full details. N/A

	Section	2 – Ceded Reinsurance Report – Part A	
	(1)	Does the company have any reinsurance agreements in effect under which reinsurance for reasons other than nonpayment of premium or other similar	• • • • • • • • • • • • • • • • • • • •
		Yes () No $(X)$	
		a. If yes, what is the estimated amount of the aggregate reduction in serinsurer as of the date of this statement, for those agreements in which the reporting entity to the reinsurer, and for which such obligation is the reporting entity may consider the current or anticipated experience estimate. N/A	h cancellation results in a net obligation of not presently accrued? Where necessary,
		b. What is the total amount of reinsurance credits taken, whether as an as agreements in this statement? $N/A$	set or as a reduction of liability for these
	(2)	Does the reporting entity have any reinsurance agreements in effect such through the statement date may result in a payment to the reinsurer of an offset of mutual credits from other reinsurance agreements with the same collected under the reinsured policies?	nounts that, in aggregate and allowing for
		Yes ( ) No (X)	
		If yes, give full details. N/A	
	Section	3 – Ceded Reinsurance Report – Part B	
	(1)	What is the estimated amount of the aggregate reduction in surplus, (for the insurer may unilaterally cancel for reasons other than for nonpaymen are reflected in Section 2 above) of termination of ALL reinsurance agreen statement? Where necessary, the company may consider the current or reinsured in making this estimate. N/A	t of premium or other similar credits that nents, by either party, as of the date of this
	(2)	Have any new agreements been executed or existing agreements amen statement, to include policies or contracts that were in force or which company as of the effective date of the agreement?	
		Yes () No $(X)$	
		If yes, what is the amount of reinsurance credit, whether an asset or a reduce agreements or amendments? N/A	ction of liability, taken for such new
B.	The Cor	mpany did not have uncollectible reinsurance at December 31, 2022 or 2021	
C.	The Cor	mpany did not have any commutation of ceded reinsurance at December 31,	2022 or 2021.
D.	The Cor or 2021.	mpany's certified reinsurer's rating has not been downgraded or its status su .	abject to revocation at December 31, 2022
E.	Reinsur	ance Credit	
	same re	the Company reinsured any risk with any other entity under a reinsurance insurer or its affiliates) that is subject to Appendix A-791, Life and Health on that limits the reinsurer's assumption of significant risks identified in App	Reinsurance Agreements, and includes a
			Yes □ No ☑

(2) Has the Company reinsured any risk with any other entity under a reinsurance contract (or multiple contracts with the same reinsurer or its affiliates) that is not subject to Appendix A-791, for which reinsurance accounting was applied and includes a provision that limits the reinsurer's assumption of risk?

Yes ☑ No □

If yes, indicate the number of reinsurance contracts to which such provisions apply: 1

If yes, indicate whether the reinsurance credit was reduced for the risk-limiting features.

Yes  $\square$  No  $\boxtimes$  N/A  $\square$ 

(3) Does the Company have any reinsurance contracts (other than reinsurance contracts with a federal or state facility) that contain one or more of the following features which may result in delays in payment in form or in fact:

- Provisions which permit the reporting of losses, or settlements are made, less frequently than quarterly or payments due from the reinsurer are not made in cash within ninety (90) days of the settlement date (unless there is no activity during the period).

• Payment schedule, accumulating retentions from multiple years or any features inherently designed to delay timing of the reimbursement to the ceding entity.			
		Yes □	No <b>☑</b>
(4) Has the Company reflected reinsurance accounting credit for any contracts that are not subject to yearly renewable term reinsurance, which meet the risk transfer requirements of SSAP No. 61R?	o Append	lix A-791	and not
		Yes □	l No ☑
(5) Has the Company ceded any risk, which is not subject to Appendix A-791 and not yearly reunder any reinsurance contract (or multiple contracts with the same reinsurer or its affiliates) during financial statements, and either:			
(a) Accounted for that contract as reinsurance under statutory accounting principles (SAP generally accepted accounting principles (GAAP); or	) and as	a deposi	it under
	Yes □	No ☑	N/A □
(b) Accounted for that contract as reinsurance under GAAP and as a deposit under SAP?			
	Yes □	No ☑	N/A □

(6) If the answer to item (5)(a) or item (5)(b) is yes, include relevant information regarding GAAP to SAP differences from the accounting policy footnote to the audited statutory-basis financial statements to explain why the contract(s) is treated differently for GAAP and SAP below: Not Applicable.

### 24. Retrospectively Rated Contracts and Contracts Subject to Redetermination

A. Through annual contracts with CMS, the Company's Medicare Advantage revenues ultimately received for each member are based on that member's health status and demographic characteristics, as determined via the CMS risk adjustment process, under which the Company regularly submits risk adjustment data to CMS. Under the risk adjustment process, the Company records a receivable for future revenues that it expects to receive from CMS in the following year, after the final reconciliation of risk adjustment data for the current contract year is complete. These amounts are recognized in the current year as premiums under contracts subject to redetermination. In addition, the Company's Medicare Advantage contracts are subject to retrospective rating provisions under which the Company and CMS share in amounts above and below agreedupon target medical benefit ratios.

Premium revenue subject to the minimum MLR rebate requirements of the ACA is recorded net of the estimated minimum MLR rebates for the current calendar year. The Company estimates the minimum MLR rebates by projecting MLRs for certain markets, as defined by the ACA, for each state in which the Company operates. The claims and premiums used in estimating such rebates are modified for certain adjustments allowed by the ACA and include a statistical credibility adjustment for those states with a number of members that is not statistically credible.

- B. Accrued retrospective are recorded as an adjustment to earned premiums and are estimated based on calculations that compare the Company's expected financial results for the contract against the appropriate medical benefit ratio target.
- C. Contracts Subject to Retrospective Rating Features

The Company had net premiums written of \$399,347,576 that were subject to retrospective rating features for the year ending December 31, 2022 representing 100% of total net premiums written.

### D. Medical Loss Ratio Rebates Required Pursuant to the Public Health Service Act

		1 Individual	2 Small Group Employer	3 Large Group Employer	4 Other Categories with rebates	5 Total
Prior	Reporting Year					
(1)	Medical Loss Ratio Rebates Incurred				\$ (1,217,681)	\$ (1,217,681)
(2)	Medical Loss Ratio Rebates Paid					
(3)	Medical Loss Ratio Rebates Unpaid				246,986	246,986
(4)	Plus reinsurance assumed amounts	XXX	XXX	XXX	XXX	
(5)	Less reinsurance ceded amounts	XXX	XXX	XXX	XXX	
(6)	Rebates Unpaid net of reinsurance	XXX	XXX	XXX	XXX	246,986
Curr	ent Reporting Year-to-Date					
(1)	Medical Loss Ratio Rebates Incurred	<b>\$</b> —	\$	\$ —	\$	\$
(2)	Medical Loss Ratio Rebates Paid	_	_	_	246,986	246,986
(3)	Medical Loss Ratio Rebates Unpaid	_	_	_	_	_
(4)	Plus reinsurance assumed amounts	XXX	XXX	XXX	XXX	_
(5)	Less reinsurance ceded amounts	XXX	XXX	XXX	XXX	_
(6)	Rebates Unpaid net of reinsurance	XXX	XXX	XXX	XXX	_

### E. Risk Sharing Provisions of the Affordable Care Act ("ACA")

- (1) Did the reporting entity write accident and health insurance premium which is subject to the ACA risk sharing provisions (YES/NO)? Yes [] No [X]
- (2) through (5): Not applicable.

### 25. Change in Incurred Claims and Claims Adjustment Expense

The following table shows the components of the change in claims unpaid, unpaid claims adjustment expense and aggregate health claim reserves for the years ended December 31, 2022 and 2021.

	2022	2021
Balance, January 1	\$ 17,094,792 \$	3,128,367
Health care receivable	 (1,477,384)	(241,051)
Balance, January 1, net of health care receivable	15,617,408	2,887,316
Incurred related to:		
Current year	357,611,268	116,689,289
Prior years	 (7,318,326)	(528,000)
Total incurred	350,292,942	116,161,289
Paid related to:		
Current year	306,731,683	100,922,570
Prior years	 9,093,775	2,508,627
Total paid	315,825,458	103,431,197
Balance, December 31, net of health care receivable	50,084,892	15,617,408
Health care receivable	 6,021,228	1,477,384
Balance, December 31	\$ 56,106,120 \$	17,094,792

- A. Reserves for incurred claims and claim adjustment expenses attributable to insured events of prior years decreased by \$7,318,326 in 2022 and \$528,000 in 2021. Changes in prior periods' estimates represents the effect of favorable development of prior period health care cost estimates on current year net income, at each financial statement date. The favorable development of these reserves is primarily a result of the actual claim submission times for health care claims being shorter than the Company had anticipated, as well as lower than expected health care cost trends in determining claims unpaid at prior financial statement date for both 2022 and 2021. Original estimates are increased or decreased, as additional information becomes known regarding individual claims. Included in this decrease, the Company experienced \$7,318,326 of favorable prior year claim development on retrospectively rated policies. However, the business to which it relates is subject to premium adjustments.
- B. There has been no significant change in the Company's methodologies and assumptions used in calculating the liability for unpaid claims and claim adjustment expenses.

### 26. Intercompany Pooling Arrangements

The Company did not have any intercompany pooling arrangements at December 31, 2022 or 2021.

### 27. Structured Settlements

The Company did not have any structured settlements at December 31, 2022 or 2021.

### 28. Health Care Receivables

#### A. Pharmaceutical Rebate Receivables

The Company receives pharmaceutical rebates through an agreement with AHM. AHM has contractual agreements with CVS Caremark for rebates, which cover the Company's membership as well as the membership of other affiliates. The Company receives those rebates from AHM that relate to the Company's membership. The Company estimates pharmaceutical rebate receivables based upon the historical payment trends, actual utilization and other variables. Actual rebates collected are applied to the collection periods below, using a first in first out methodology. At December 31, 2022 and 2021, the Company had pharmaceutical rebate receivables of \$4,027,814 and \$1,087,300, respectively (refer to the Company's accounting practices related to pharmaceutical rebate receivables in Note 1).

The following table discloses the quarterly revenue and subsequent cash collections relating to the pharmaceutical rebates discussed in Note 10:

Quarter	Estimated Pharmacy Rebates as Reported on Financial Statements	Pharmacy Rebates as Billed or Otherwise Confirmed	Actual Rebates Received Within 90 Days of Billing		Actual Rebates Received Within 91 to 180 Days of Billing	Actual Rebates Received More Than 180 Days After Billing
12/31/2022	\$ 11,860,018	\$ —	\$ 7,896,741	1	\$	\$ —
09/30/2022	10,979,387	10,818,681	10,820,888		_	_
06/30/2022	9,533,046	9,440,256	9,399,934		_	_
03/31/2022	7,962,306	7,667,459	7,644,248		_	_
12/31/2021	3,178,159	3,137,006	3,136,565		_	_
09/30/2021	2,953,006	2,855,990	2,855,549		_	_
06/30/2021	2,458,942	2,401,625	2,401,184		_	_
03/31/2021	1,806,558	1,800,733	1,800,292		_	_
12/31/2020	575,696	575,138	574,776		_	_
09/30/2020	511,932	515,861	515,499		_	_
06/30/2020	405,470	408,946	408,584		_	_
03/31/2020	284,076	289,165	288,803		_	_

<sup>&</sup>lt;sup>1</sup> Represents a portion of the estimated rebates for the quarter ending December 31, 2022, which were paid by AHM to the Company prior to December 31, 2022 and invoicing in 2023.

### B. Risk sharing receivables

The Company did not have any admitted risk sharing receivables at December 31, 2022 or 2021.

### Other receivables

Pharmacy Direct and Indirect Remuneration ("DIR") Generic

The Company receives retrospective generic performance network rebates ("PNR") on its Medicare business through an agreement with AHM. AHM has contractual agreements with network pharmacies for PNR. The PNR is performance based upon whether the participating pharmacies have met certain pre-established rates specified in the contract. The PNR is calculated by multiplying the applicable claims with a variable network rate based on the actual performance. The PNR receivables fit the category of other health care receivables per SSAP No. 84 - Health Care and Government Insured Plan Receivables.

### Pharmacy DIR Brand

The Company receives retrospective brand PNR on its Medicare business through an agreement with AHM. As mentioned above, AHM has contractual agreements with network pharmacies for PNR. The program collects varying percentages of brand ingredient cost from pharmacies, depending how well they perform on adherence measures, including stars-related measures. The PNR agreement for 2020 has three performance measurement periods ending April 30, August 31 and December 31, respectively. The PNR receivables fit the category of other health care receivables per SSAP No. 84 - *Health Care and Government Insured Plan Receivables*.

### 29. Participating Policies

The Company did not have any participating policies at December 31, 2022 or 2021.

### 30. <u>Premium Deficiency Reserves</u>

<u>December 31, 2022</u>

1. Liability carried for premium deficiency reserves

\$6,533,095

2. Date of the most recent evaluation of this liability

12/31/2022

3. Was anticipated investment income utilized in the calculation?

No

### 31. Anticipated Salvage and Subrogation

The Company did not reduce its liability for unpaid claims/losses by any estimated anticipated salvage and subrogation at December 31, 2022 or 2021 as the Company records salvage and subrogation on a paid basis when cash is received.

# **GENERAL INTERROGATORIES**

# PART 1 - COMMON INTERROGATORIES GENERAL

1.1 Is the reporting entity a member of an Insurance Holding Company System consisting of two or more affiliated persons, one or more of is an insurer?						No [	1
	If yes, complete Schedule Y, Parts 1, 1A, 2 and 3.			•	•		•
1.2	If yes, did the reporting entity register and file with its domiciliary State Ins such regulatory official of the state of domicile of the principal insurer in th providing disclosure substantially similar to the standards adopted by the its Model Insurance Holding Company System Regulatory Act and model subject to standards and disclosure requirements substantially similar to t	ne Holding Company System, a registration statement National Association of Insurance Commissioners (NAIC) in regulations pertaining thereto, or is the reporting entity	Yes [ X	] No [	]	N/A	[ ]
1.3	State Regulating?			Mich	igan		
1.4	Is the reporting entity publicly traded or a member of a publicly traded group	up?		Yes [ )	( ]	No [	]
1.5	If the response to 1.4 is yes, provide the CIK (Central Index Key) code iss	sued by the SEC for the entity/group.		000006	34800	3	
2.1	Has any change been made during the year of this statement in the charter reporting entity?			Yes [	]	No [	Х]
2.2	If yes, date of change:						
3.1	State as of what date the latest financial examination of the reporting entit	ty was made or is being made		12/31	/2020	)	
3.2	State the as of date that the latest financial examination report became as entity. This date should be the date of the examined balance sheet and no			12/31	<u>/202(</u>	)	
3.3	State as of what date the latest financial examination report became avail domicile or the reporting entity. This is the release date or completion date examination (balance sheet date).	e of the examination report and not the date of the		05/23/	/2022	2	
3.4	By what department or departments?  Michigan Department of Insurance and Financial Services						
3.5	Have all financial statement adjustments within the latest financial examin statement filed with Departments?		Yes [	] No [	]	N/A	[ X ]
3.6	Have all of the recommendations within the latest financial examination re	eport been complied with?	Yes [ X	] No [	]	N/A	[ ]
4.1		es of the reporting entity), receive credit or commissions for or co asured on direct premiums) of: of new business?		Yes [ Yes [			
4.2	receive credit or commissions for or control a substantial part (more than premiums) of:			Yes [	1	No I	Y 1
		als?		-	_	No [	-
5.1	Has the reporting entity been a party to a merger or consolidation during t If yes, complete and file the merger history data file with the NAIC.	the period covered by this statement?		Yes [	]	No [	Х ]
5.2	If yes, provide the name of the entity, NAIC Company Code, and state of ceased to exist as a result of the merger or consolidation.	domicile (use two letter state abbreviation) for any entity that has	5				
	1 Name of Entity	NAIC Company Code State of Domicile					
6.1	Has the reporting entity had any Certificates of Authority, licenses or regis revoked by any governmental entity during the reporting period?	strations (including corporate registration, if applicable) suspende		Yes [	]	No [	Х]
6.2	If yes, give full information:						
7.1	Does any foreign (non-United States) person or entity directly or indirectly	control 10% or more of the reporting entity?		Yes [	]	No [	Х ]
7.2	If yes, 7.21 State the percentage of foreign control;	entity is a mutual or reciprocal, the nationality of its manager or	······ <u> </u>				%
	1 Nationality	2 Type of Entity					

# **GENERAL INTERROGATORIES**

8.1 8.2	Is the company a subsidiary of a depository institution holding compan If the response to 8.1 is yes, please identify the name of the DIHC.					Yes [	]	No [	Χ]	
8.3 8.4	Is the company affiliated with one or more banks, thrifts or securities fill fresponse to 8.3 is yes, please provide below the names and location regulatory services agency [i.e. the Federal Reserve Board (FRB), the Insurance Corporation (FDIC) and the Securities Exchange Commission	n (city and state of the main office) of any affiliates re Office of the Comptroller of the Currency (OCC), th	egulated e Feder	by a fe	deral	Yes [	]	No [	Х ]	
	1	2	3	4	5	6				
	Affiliate Name	Location (City, State)	FRB	OCC	FDIC	SEC	-			
8.5	Is the reporting entity a depository institution holding company with significant Reserve System or a subsidiary of the depository institution holding company with significant reporting the state of the depository institution holding company with significant reporting the state of the depository institution holding company with significant reporting the state of the depository institution holding company with significant reporting the state of the depository institution holding company with significant reporting the state of the depository institution holding company with significant reporting the state of the depository institution holding company with significant reporting the state of the depository institution holding company with significant reporting the state of the depository institution holding company with significant reporting the state of the depository institution holding company with significant reporting the state of the depository institution holding company with significant reporting the state of the depository institution holding company with significant reporting the state of the depository institution holding company with the depository institution and the depository institution in the depository in the depos	olding company?				Yes [	]	No [	Х]	
8.6	If response to 8.5 is no, is the reporting entity a company or subsidiary Federal Reserve Board's capital rule?	of a company that has otherwise been made subject	ct to the		Vac [	] No [	y 1	NI/A	1	1
9.	What is the name and address of the independent certified public according to the independent certified to the independent certifi				165 [	] NO [	۸ ]	IN/ A	١ ١	1
	Ernst & Young LLP; One Manhattan West; New York, NY 10001									
10.1	Has the insurer been granted any exemptions to the prohibited non-au requirements as allowed in Section 7H of the Annual Financial Reporting or regulation?	ing Model Regulation (Model Audit Rule), or substar	ntially si	milar sta	ate	Yes [	]	No [	Х]	
10.2	If the response to 10.1 is yes, provide information related to this exemp	•								
10.3	Has the insurer been granted any exemptions related to the other requallowed for in Section 18A of the Model Regulation, or substantially sin	uirements of the Annual Financial Reporting Model F milar state law or regulation?	Regulati	on as		Yes [	]	No [	Х ]	
10.4	If the response to 10.3 is yes, provide information related to this exempt	•								
10.5 10.6	Has the reporting entity established an Audit Committee in compliance If the response to 10.5 is no or n/a, please explain	e with the domiciliary state insurance laws?			Yes [ X	] No [	]	N/A	] /	]
11. 12.1	What is the name, address and affiliation (officer/employee of the repofirm) of the individual providing the statement of actuarial opinion/certif Kyle Richardson, A.S.A., M.A.A.A.; CVS; 151 Farmington Ave., RE52; Does the reporting entity own any securities of a real estate holding co	orting entity or actuary/consultant associated with an fication?  Hartford, CT 06156; Appointed Actuary  Company or otherwise hold real estate indirectly?	actuari	al consu	ulting	Yes [	]	No [	Х]	
		estate holding company								
		rcels involved								^
12.2	If, yes provide explanation:	justed carrying value				<b></b>				U
13.	FOR UNITED STATES BRANCHES OF ALIEN REPORTING ENTITI									
13.1	What changes have been made during the year in the United States m N/A									
13.2	, ,	, ,				Yes [	]	No [	]	
13.3	Have there been any changes made to any of the trust indentures duri	• ,				Yes [	]	-	-	
13.4	If answer to (13.3) is yes, has the domiciliary or entry state approved the					] No [	]	N/A	\ [	]
14.1	Are the senior officers (principal executive officer, principal financial of similar functions) of the reporting entity subject to a code of ethics, whi a. Honest and ethical conduct, including the ethical handling of actual relationships; b. Full, fair, accurate, timely and understandable disclosure in the period	ich includes the following standards?or apparent conflicts of interest between personal ar	nd profe			Yes [ X	( ]	No [	]	
	c. Compliance with applicable governmental laws, rules and regulation									
	d. The prompt internal reporting of violations to an appropriate person	or persons identified in the code; and								
14.11	e. Accountability for adherence to the code.  If the response to 14.1 is No, please explain:									
440	Use the sade of this feet and a second of the second of th					V	, ,			
	Has the code of ethics for senior managers been amended?	ent(s). e which resulted in the following updates/revisions: of el" to "Colleague Relations" and updating related co	general intact in	formatio	on,	Yes [ X	( ]	No [	J	
14.3	inclusion of a Commitment to Quality and Safety section, updated Hea Have any provisions of the code of ethics been waived for any of the s					Yes [	1	No ſ	X 1	
	If the response to 14.3 is yes, provide the nature of any waiver(s).	-					•		•	

# **GENERAL INTERROGATORIES**

1	2	<u> </u>	3		
1 America Banker	n S		3	4	
Associati (ABA) Rou					
Númbe	r Issuing or Confirming Bank Name		That Can Trigger the Letter of Credit	Amou	
	BOA	RD OF DIRECTOR	S		
thereof?	nase or sale of all investments of the reporting entity passe	d upon either by the board	of directors or a subordinate committee	Yes [ X ]	No
	porting entity keep a complete permanent record of the pr			Yes [ X ]	No
Has the repart of any	orting entity an established procedure for disclosure to its of its officers, directors, trustees or responsible employees	board of directors or trustee that is in conflict or is likely	es of any material interest or affiliation on the to conflict with the official duties of such		
		FINANCIAL			
Has this sta	atement been prepared using a basis of accounting other the Principles)?	han Statutory Accounting P	rinciples (e.g., Generally Accepted	Yes [ ]	No
	nt loaned during the year (inclusive of Separate Accounts,				
			20.12 To stockholders not officers	\$	
			20.13 Trustees, supreme or grand		
			(Fraternal Only)	\$	
	nt of loans outstanding at the end of year (inclusive of Sep	arate Accounts, exclusive of	of	_	
policy loans	3):		20.21 To directors or other officers		
			20.22 To stockholders not officers	\$	
			20.23 Trustees, supreme or grand (Fraternal Only)	e	
Woro any	ssets reported in this statement subject to a contractual of	oligation to transfer to anoth		\$	
obligation b	eing reported in the statement?	nigation to transfer to anoth	er party without the hability for such	Yes [ ]	No
	the amount thereof at December 31 of the current year:		21.21 Rented from others		
	•		21.22 Borrowed from others		
			21.23 Leased from others		
			21.24 Other		
guaranty as	tatement include payments for assessments as described association assessments?		structions other than guaranty fund or	Yes [ X ]	No
If answer is	yes:		2.21 Amount paid as losses or risk adjustmen		
			2.22 Amount paid as expenses		
			2.23 Other amounts paid		
	porting entity report any amounts due from parent, subsidi				
	ate any amounts receivable from parent included in the Pa			\$	
	surer utilize third parties to pay agent commissions in which			Vac [ 1	Ma
	nse to 24.1 is yes, identify the third-party that pays the age			Yes [ ]	No
	,,,				
		Is the			
		Third-Party Ag			
	Name of Third Porty	a Related Par	rty		
	Name of Third-Party	(Yes/No)			

# 27.2

# **GENERAL INTERROGATORIES**

25.02	If no, give full and complete information relating thereto		
25.03	For securities lending programs, provide a description of the whether collateral is carried on or off-balance sheet. (an alter	program including value for collateral and amount of loaned securities, and native is to reference Note 17 where this information is also provided)	
25.04		mount of collateral for conforming programs as outlined in the Risk-Based Capital	\$
25.05	For the reporting entity's securities lending program, report a	mount of collateral for other programs.	\$(
25.06	Does your securities lending program require 102% (domestioutset of the contract?	ic securities) and 105% (foreign securities) from the counterparty at the	] No [ ] N/A [ X
25.07	Does the reporting entity non-admit when the collateral receives	ved from the counterparty falls below 100%? Yes [	] No [ ] N/A [ X
25.08		ending agent utilize the Master Securities lending Agreement (MSLA) to Yes [	] No [ ] N/A [ X
25.09	For the reporting entity's securities lending program state the	amount of the following as of December 31 of the current year:	
	25.092 Total book adjusted/carrying value of	al assets reported on Schedule DL, Parts 1 and 2freinvested collateral assets reported on Schedule DL, Parts 1 and 2eported on the liability page.	\$
26.1	control of the reporting entity or has the reporting entity sold of	g entity owned at December 31 of the current year not exclusively under the or transferred any assets subject to a put option contract that is currently in 25.03).	Yes [ X ] No [ ]
26.2	If yes, state the amount thereof at December 31 of the currer	26.21 Subject to repurchase agreements	\$
		26.32 Other	\$
26.3	For category (26.26) provide the following:		
26.3	For category (26.26) provide the following:  1  Nature of Restriction	2 Description	3 Amount
26.3	1	Description	Amount
	1 Nature of Restriction	Description	Amount
27.1	Nature of Restriction  Does the reporting entity have any hedging transactions reporting entity has a comprehensive description of the hedging programment.	Description	Amount  Yes [ ] No [ X ]
27.1 27.2	Nature of Restriction  Does the reporting entity have any hedging transactions reporting	Description	Amount  Yes [ ] No [ X ]
27.1 27.2	1 Nature of Restriction  Does the reporting entity have any hedging transactions reporting yes, has a comprehensive description of the hedging progrif no, attach a description with this statement.  7.3 through 27.5: FOR LIFE/FRATERNAL REPORTING ENT	Description	Amount  Yes [ ] No [ X ]
27.1 27.2 JINES 2	1 Nature of Restriction  Does the reporting entity have any hedging transactions reporting yes, has a comprehensive description of the hedging progrif no, attach a description with this statement.  7.3 through 27.5: FOR LIFE/FRATERNAL REPORTING ENT	Description  orted on Schedule DB?  am been made available to the domiciliary state?	Amount  Yes [ ] No [ X ]  ] No [ ] N/A [ X ]  Yes [ ] No [ ]
27.1 27.2 INES 2 27.3	Nature of Restriction  Does the reporting entity have any hedging transactions reporting entity have any hedging transactions reporting yes, has a comprehensive description of the hedging prograf no, attach a description with this statement.  7.3 through 27.5: FOR LIFE/FRATERNAL REPORTING ENT Does the reporting entity utilize derivatives to hedge variable of the response to 27.3 is YES, does the reporting entity utilize	Description  orted on Schedule DB?	Amount  Yes [ ] No [ X ]  ] No [ ] N/A [ X  Yes [ ] No [ ]  Yes [ ] No [ ]  Yes [ ] No [ ]
27.1 27.2 INES 2 27.3	Nature of Restriction  Nature of Restriction  Does the reporting entity have any hedging transactions reporting entity have any hedging transactions reporting yes, has a comprehensive description of the hedging prograf for no, attach a description with this statement.  7.3 through 27.5: FOR LIFE/FRATERNAL REPORTING ENT Does the reporting entity utilize derivatives to hedge variable of the response to 27.3 is YES, does the reporting entity utilize the responding YES to 27.41 regarding utilizing the special and following:  The reporting entity has obtained explicit approval for the reporting entity entity the reporting entity entity the reporting entity	Description  orted on Schedule DB?	Amount  Yes [ ] No [ X ]  ] No [ ] N/A [ X  Yes [ ] No [ ]  Yes [ ] No [ ]
27.1 27.2 INES 2 27.3 27.4	Nature of Restriction  Nature of Restriction  Does the reporting entity have any hedging transactions reported by the reporting entity have any hedging transactions reported by the reporting entity with this statement.  7.3 through 27.5: FOR LIFE/FRATERNAL REPORTING ENT Does the reporting entity utilize derivatives to hedge variable of the response to 27.3 is YES, does the reporting entity utilize the response to 27.3 is YES, does the reporting entity utilize the response to 27.41 regarding utilizing the special action of the reporting entity has obtained explicit approval from the Hedging strategy subject to the special accounting processors and provides the impact of the hedging strates and provides the impact of the hedging strates.  Financial Officer Certification has been obtained which indicent the response of the second of the response of the hedging strategy subject to the special accounting provides the impact of the hedging strategy the response of the hedging strategy of the response of the hedging strategy and provides the impact of the hedging strategy of the response of the hedging strategy and provides the impact of the hedging strategy of the response of the hedging strategy of the provides the impact of the hedging strategy of the provides the impact of the hedging strategy of the provides the impact of the hedging strategy of the provides the impact of the hedging strategy of the provides the impact of the hedging strategy of the provides the impact of the hedging strategy of the provides the impact of the hedging strategy of the provides the impact of the hedging strategy of the provides the impact of the hedging strategy of the provides the impact of the hedging strategy of the provides the impact of the hedging strategy of the provides the impact of the hedging strategy of the provides the impact of the hedging strategy of the provides the impact of the hedging strategy of the provides the impact of the hedging strategy of the provides the impact of the provides the impact of the provides t	am been made available to the domiciliary state?	Amount  Yes [ ] No [ X ]  ] No [ ] N/A [ X  Yes [ ] No [ ]
27.1 27.2 INES 2 27.3 27.4	Nature of Restriction  Nature of Restriction  Does the reporting entity have any hedging transactions reported by the second of the hedging program of the nedging program of the nedging program of the nedging program of the nedging program of the nedge variable of the reporting entity utilize derivatives to hedge variable of the response to 27.3 is YES, does the reporting entity utilize the response to 27.3 is YES, does the reporting entity utilize the response to 27.3 is YES, does the reporting entity utilize the response to 27.41 regarding utilizing the special actification in the special accounting program of the nedging strategy subject to the special accounting program of the nedging strategy within VM-21 and that the Clearly its actual day-to-day risk mitigation efforts.	Description  Inted on Schedule DB?	Amount  Yes [ ] No [ X ]  ] No [ ] N/A [ X  Yes [ ] No [ ]
27.1 27.2 INES 2 27.3 27.4	Nature of Restriction  Nature of Restriction  Does the reporting entity have any hedging transactions reported in the properties of the hedging program of the hedging entity utilized erivatives to hedge variable of the response to 27.3 is YES, does the reporting entity utilized by responding YES to 27.41 regarding utilizing the special action of the hedging entity has obtained explicit approval from the hedging strategy subject to the special accounting properties of the hedging strategy subject to the special accounting properties of the hedging strategy within the hedging strategy within VM-21 and that the Clearly its actual day-to-day risk mitigation efforts.  Were any preferred stocks or bonds owned as of December issuer, convertible into equity?	am been made available to the domiciliary state? Yes [  TITIES ONLY:  annuity guarantees subject to fluctuations as a result of interest rate sensitivity?.  e:  27.41 Special accounting provision of SSAP No. 108	Amount  Yes [ ] No [ X ]  ] No [ ] N/A [ X  Yes [ ] No [ ]
27.1 27.2 IINES 2 27.3 27.4 27.5	Nature of Restriction  If yes, has a comprehensive description of the hedging progration of the nature of the hedging progration of the nature of the hedging progration of the nature of the hedging progration of the reporting entity utilize derivatives to hedge variable of the response to 27.3 is YES, does the reporting entity utilize the response to 27.3 is YES, does the reporting entity utilize of the response to 27.41 regarding utilizing the special accounting the Hedging strategy subject to the special accounting the Actuarial certification has been obtained which indice reserves and provides the impact of the hedging strategy within VM-21 and that the Clearly its actual day-to-day risk mitigation efforts.  Were any preferred stocks or bonds owned as of December issuer, convertible into equity?  If yes, state the amount thereof at December 31 of the currer excluding items in Schedule E - Part 3 - Special Deposits, re offices, vaults or safety deposit boxes, were all stocks, bonds custodial agreement with a qualified bank or trust company in	am been made available to the domiciliary state? Yes [  TITIES ONLY:  annuity guarantees subject to fluctuations as a result of interest rate sensitivity? .  e:  27.41 Special accounting provision of SSAP No. 108	Amount  Yes [ ] No [ X ]  ] No [ ] N/A [ X  Yes [ ] No [ ]
27.1 27.2 INES 2 27.3 27.4 27.5	Nature of Restriction  Nature of Restriction  Does the reporting entity have any hedging transactions reported in the programment of the hedging programment of the programment of the hedging programment of the programment of the hedging	am been made available to the domiciliary state?	Amount  Yes [ ] No [ X ]  ] No [ ] N/A [ X ]  Yes [ ] No [ ]
27.1 27.2 INES 2 27.3 27.4 27.5	Nature of Restriction  Nature of Restriction  Does the reporting entity have any hedging transactions reported for the properties of the hedging program of the nedgeng program of the nedgeng program of the reporting entity utilize derivatives to hedge variable of the response to 27.3 is YES, does the reporting entity utilize the response to 27.3 is YES, does the reporting entity utilize the response to 27.3 is YES, does the reporting entity utilize the response to 27.3 is YES, does the reporting entity utilize the response to 27.3 is YES, does the reporting entity utilize the response to 27.3 is YES, does the reporting entity utilize the response to 27.3 is YES, does the reporting entity utilize the response to 27.3 is YES, does the reporting entity utilize the response of the special accounting properties of the special accounting properties of the hedging strategy subject to the special accounting properties and provides the impact of the hedging strategy within the special accounting properties of the hedging strategy within VM-21 and that the Clearly its actual day-to-day risk mitigation efforts.  Were any preferred stocks or bonds owned as of December issuer, convertible into equity?  If yes, state the amount thereof at December 31 of the currer excluding items in Schedule E - Part 3 - Special Deposits, reoffices, vaults or safety deposit boxes, were all stocks, bonds custodial agreement with a qualified bank or trust company in Outsourcing of Critical Functions, Custodial or Safekeeping A For agreements that comply with the requirements of the NA	am been made available to the domiciliary state?	Amount  Yes [ ] No [ X ]  ] No [ ] N/A [ X ]  Yes [ ] No [ ]

# **GENERAL INTERROGATORIES**

9.02	For all agreements that do not comply with the requirements of the NAIC Financial Condition Examiners Handbook, provide the name, location
	and a complete explanation:

1	2	3
Name(s)	Location(s)	Complete Explanation(s)

29.03	Have there been any changes, including name changes, in the custodian(s) identified in 29.01 during the current year?	Yes [	]	No	[ X ]
29.04	If yes, give full and complete information relating thereto:				

1	2	3	4
Old Custodian	New Custodian	Date of Change	Reason

29.05 Investment management – Identify all investment advisors, investment managers, broker/dealers, including individuals that have the authority to make investment decisions on behalf of the reporting entity. For assets that are managed internally by employees of the reporting entity, note as such. ["...that have access to the investment accounts"; "...handle securities"]

1	2
Name of Firm or Individual	Affiliation
Derek S. Blunt as Senior Investment Officer	A

29.06 For those firms or individuals listed in the table for 29.05 with an affiliation code of "A" (affiliated) or "U" (unaffiliated), provide the information for the table below.

1	2	3	4	5
				Investment
				Management
Central Registration				Agreement
Depository Number	Name of Firm or Individual	Legal Entity Identifier (LEI)	Registered With	(IMA) Filed
N/A	Derek S. Blunt	N/A	Not registered	N0
			•	

30.2 If yes, complete the following schedule:

1	2	3
CUSIP#	Name of Mutual Fund	Book/Adjusted Carrying Value
30.2999 - Total		0

30.3 For each mutual fund listed in the table above, complete the following schedule:

1	2	3	4
		Amount of Mutual	
		Fund's Book/Adjusted	
		Carrying Value	
	Name of Significant Holding of the	Attributable to the	Date of
Name of Mutual Fund (from above table)	Mutual Fund	Holding	Valuation

# **GENERAL INTERROGATORIES**

31. Provide the following information for all short-term and long-term bonds and all preferred stocks. Do not substitute amortized value or statement value for fair value.

	1	2	3
			Excess of Statement
			over Fair Value (-), or
	Statement (Admitted)		Fair Value over
	Value	Fair Value	Statement (+)
31.1 Bonds	114,005,287	112,847,478	(1,157,809)
31.2 Preferred stocks	0		0
31.3 Totals	114,005,287	112,847,478	(1,157,809)

31.4	Describe the sources or methods utilized in determining the fair values:  Fair value of long term bonds and preferred stocks are determined based on quoted market prices when available, fair values using valuation methodologies based on available and observable market information or by using matrix pricing. If quoted market prices are not available, we determine fair value using broker quoted or an internal analysis of each investment's financial performance and cash flow projections. Short Term investments are carried at amortized cost which approximated fair value. The carrying value of cash equivalents approximated fair value.				
32.1	Was the rate used to calculate fair value determined by a broker or custodian for any of the securities in Schedule D?	Yes [	]	No [ X	]
32.2	If the answer to 32.1 is yes, does the reporting entity have a copy of the broker's or custodian's pricing policy (hard copy or electronic copy) for all brokers or custodians used as a pricing source?	Yes [	]	No [	]
32.3	If the answer to 32.2 is no, describe the reporting entity's process for determining a reliable pricing source for purposes of disclosure of fair value for Schedule D:				
33.1 33.2	Have all the filing requirements of the Purposes and Procedures Manual of the NAIC Investment Analysis Office been followed?	Yes [	Х ]	No [	]
34.	By self-designating 5GI securities, the reporting entity is certifying the following elements of each self-designated 5GI security:  a. Documentation necessary to permit a full credit analysis of the security does not exist or an NAIC CRP credit rating for an FE or PL security is not available.  b. Issuer or obligor is current on all contracted interest and principal payments.  c. The insurer has an actual expectation of ultimate payment of all contracted interest and principal.	V .	,	N. F. V	1
35.	Has the reporting entity self-designated 5GI securities?  By self-designating PLGI securities, the reporting entity is certifying the following elements of each self-designated PLGI security:  a. The security was purchased prior to January 1, 2018.  b. The reporting entity is holding capital commensurate with the NAIC Designation reported for the security.  c. The NAIC Designation was derived from the credit rating assigned by an NAIC CRP in its legal capacity as a NRSRO which is shown on a current private letter rating held by the insurer and available for examination by state insurance regulators.  d. The reporting entity is not permitted to share this credit rating of the PL security with the SVO.				
36.	Has the reporting entity self-designated PLGI securities?  By assigning FE to a Schedule BA non-registered private fund, the reporting entity is certifying the following elements of each self-designated FE fund:	Yes [	]	No [ X	1
	<ul> <li>a. The shares were purchased prior to January 1, 2019.</li> <li>b. The reporting entity is holding capital commensurate with the NAIC Designation reported for the security.</li> <li>c. The security had a public credit rating(s) with annual surveillance assigned by an NAIC CRP in its legal capacity as an NRSRO prior to January 1, 2019.</li> <li>d. The fund only or predominantly holds bonds in its portfolio.</li> <li>e. The current reported NAIC Designation was derived from the public credit rating(s) with annual surveillance assigned by an NAIC CRP in its legal capacity as an NRSRO.</li> <li>f. The public credit rating(s) with annual surveillance assigned by an NAIC CRP has not lapsed.</li> <li>Has the reporting entity assigned FE to Schedule BA non-registered private funds that complied with the above criteria?</li> </ul>	Yes [	]	No [ X	1
37.	By rolling/renewing short-term or cash equivalent investments with continued reporting on Schedule DA, Part 1 or Schedule E Part 2 (identified through a code (%) in those investment schedules), the reporting entity is certifying to the following:  a. The investment is a liquid asset that can be terminated by the reporting entity on the current maturity date.  b. If the investment is with a nonrelated party or nonaffiliate, then it reflects an arms-length transaction with renewal completed at the discretion of all involved parties.  c. If the investment is with a related party or affiliate, then the reporting entity has completed robust re-underwriting of the transaction for which documentation is available for regulator review.  d. Short-term and cash equivalent investments that have been renewed/rolled from the prior period that do not meet the criteria in 37.a - 37.c are reported as long-term investments.  Has the reporting entity rolled/renewed short-term or cash equivalent investments in accordance with these criteria?	] No	. 1	N/A [	]

# **GENERAL INTERROGATORIES**

38.1	Does the reporting entity directly hold cryptocurrencies?			. Yes [	] No [ X ]
38.2	If the response to 38.1 is yes, on what schedule are they reported?				
39.1	Does the reporting entity directly or indirectly accept cryptocurrencies as payments for	r premiums on policies?		. Yes [	] No [ X ]
39.2	If the response to 39.1 is yes, are the cryptocurrencies held directly or are they immed 39.21 Held directly			] No [ ]	
39.3	39.22 Immediately conv If the response to 38.1 or 39.1 is yes, list all cryptocurrencies accepted for payments of	. Yes [	] NO [ ]		
	1  Name of Cryptocurrency	2 Immediately Converted to USD, Directly Held, or Both	3 Accepted for Payment of Premiums		
	OTHER	?			
40.1 40.2	Amount of payments to trade associations, service organizations and statistical or rational List the name of the organization and the amount paid if any such payment represent service organizations and statistical or rating bureaus during the period covered by the	ed 25% or more of the total payme			7,619
	1		2		
	Name		unt Paid		
41.1	Amount of payments for legal expenses, if any?			\$	149,429
41.2	List the name of the firm and the amount paid if any such payment represented 25% during the period covered by this statement.	or more of the total payments for l	egal expenses		
	1 Name		2 unt Paid		
42.1	Amount of payments for expenditures in connection with matters before legislative bo	dies, officers or departments of go	overnment, if any?	\$	0
42.2	List the name of the firm and the amount paid if any such payment represented 25% connection with matters before legislative bodies, officers, or departments of governments.				
	1 Name		2 unt Paid		

# **GENERAL INTERROGATORIES**

### PART 2 - HEALTH INTERROGATORIES

1.1 1.2	Does the reporting entity have any direct Medicare Supplement Insurance in for If yes, indicate premium earned on U.S. business only.							
1.3								
1.4	Indicate amount of earned premium attributable to Canadian and/or Other Alien		\$					
1.5	Indicate total incurred claims on all Medicare Supplement Insurance.							
1.6	Individual policies:	Most current three years:	. Ψ					
1.0	individual policies.		œ.	0				
		1.61 Total premium earned						
		1.62 Total incurred claims	-					
		1.63 Number of covered lives		0				
		All years prior to most current three years:						
		1.64 Total premium earned	\$	0				
		1.65 Total incurred claims						
		1.66 Number of covered lives						
1.7	Group policies:	Most current three years:						
		1.71 Total premium earned						
		1.72 Total incurred claims	\$	0				
		1.73 Number of covered lives						
		All years prior to most current three years:						
		1.74 Total premium earned		0				
		1.75 Total incurred claims						
		1.76 Number of covered lives		0				
2.	Health Test:	1 2						
		Current Year Prior Year						
	2.1 Premium Numerator							
	2.2 Premium Denominator							
	2.3 Premium Ratio (2.1/2.2)							
	2.4 Reserve Numerator							
	2.5 Reserve Denominator							
	2.6 Reserve Ratio (2.4/2.5)	1.000						
3.1	Has the reporting entity received any endowment or gift from contracting hospital returned when, as and if the earnings of the reporting entity permits?		Yes [ ]	] No [ X ]				
3.2	If yes, give particulars:							
4.1	Have copies of all agreements stating the period and nature of hospitals', physic dependents been filed with the appropriate regulatory agency?		Vac I	] No [ X ]				
4.2	If not previously filed, furnish herewith a copy(ies) of such agreement(s). Do the	se agreements include additional benefits offered?	Yes [ ]	] No [ X ]				
5.1	Does the reporting entity have stop-loss reinsurance?		Yes [ X ]	] No [ ]				
5.2	If no, explain:							
5.3	Maximum retained risk (see instructions)	5.31 Comprehensive Medical	. \$	2.000.000				
-	, , , , , , , , , , , , , , , , , , , ,	5.32 Medical Only						
		5.33 Medicare Supplement						
		5.34 Dental & Vision						
		5.35 Other Limited Benefit Plan						
		5.36 Other						
6.	Describe arrangement which the reporting entity may have to protect subscriber hold harmless provisions, conversion privileges with other carriers, agreements agreements:	with providers to continue rendering services, and any other						
	Provider contracts contain hold harmless and continuity of coverage provisions. agreement with an affiliate of the Company							
7.1	Does the reporting entity set up its claim liability for provider services on a servi-	ce date basis?	Yes [ X ]	] No [ ]				
7.2	If no, give details							
8.	Provide the following information regarding participating providers:	8.1 Number of providers at start of reporting year 8.2 Number of providers at end of reporting year .						
9.1	Does the reporting entity have business subject to premium rate guarantees?		Yes [	] No [ X ]				
				_				
9.2	If yes, direct premium earned:	9.21 Business with rate guarantees between 15-36 months 9.22 Business with rate guarantees over 36 months						

# **GENERAL INTERROGATORIES**

10.1	Does the reporting entity have Incentive Pool, Withh		Yes [ X ] N	0 [ ]				
10.2	If yes:	sesoldshholds	\$	8,261,289 0				
11.1	Is the reporting entity organized as:			11.13 An Individ	al Group/Staff Mode dual Practice Asso Model (combination	ciation (IPA), or,	Yes [ ] M	No [ X ] No [ X ]
11.2 11.3 11.4	Is the reporting entity subject to Statutory Minimum of the state requiring such milf yes, show the amount required.	nimum capital ar	nd surplus				\$2	Michigan 8,042,688
11.5 11.6	Is this amount included as part of a contingency result the amount is calculated, show the calculation See Notes to Financial Statement - Note 21, Other I						Yes [ ] N	o [ X ]
12.	List service areas in which reporting entity is license	d to operate:						
	Clare, Cl Traverse, Kalkaska, Midland, Presque I Washtenaw Illinois Henderson McHenry, Winnebago Indiana: Clay, Cli Gibson, G Huntingto LaGrange, Monroe, M Posey, Pu Sullivan,	inton, Crawford Gratiot, Hills Lapeer, Leelan Missaukee, Monr sle, Saginaw, S , Wayne, Wexfor Boone, Bureau, , Henry, Jo Dav Mercer, Ogle, Ri More, Allen, nton, Daviess, rant, Greene, H n, Jackson, Jas Lake, LaPorte, ontgomery, Morg laski, Putnam, Tippecanoe, Ti Wayne, Wells, W	Name of Service n, Arenac, Bay, Be , Eaton, Emmet, Ge dale, Huron, Ingha au, Lenawee, Livir oe, Montmorency, C t. Clair, Sanilac, d	nzie, Charlevoix, enesee, Gladwin, C m, Iosco, Isabell gston, Macomb, Ma bakland, Oscoda, C Shiawassee, Tusc eKalb, DuPage, Gr eee, Kendall, Lake enson, Warren, Whi , Boone, Brown, C Elkhart, Fountair Hendricks, Henry, s, Johnson, Knox, i, Marion, Marshal Owen, Parke, Pil Starke, Steuben, Vermillion, Vigo	Grand  Ia, Jackson, anistee, Otsego, cola,			
13.1	Do you act as a custodian for health savings accour							
13.2	If yes, please provide the amount of custodial funds		-					
13.3	Do you act as an administrator for health savings ac							
13.4 14.1 14.2	If yes, please provide the balance of funds administed Are any of the captive affiliates reported on Schedul If the answer to 14.1 is yes, please provide the follows:	e S, Part 3, auth	_					
	1	2 NAIC	3	4	Assets 5	Supporting Reserv	e Credit	
	Company Name	Company Code	Domiciliary Jurisdiction	Reserve Credit	Letters of Credit	Trust Agreements	Other	
······								
15.	Provide the following for individual ordinary life insurceded):	ance* policies (l	J.S. business only)	15.1 D 15.2 T	Direct Premium Wri	nce assumed or ttens	\$	0
	Term(whether full und Whole Life (whether to Variable Life (with or Universal Life (with or Variable Universal Life	derwriting, limiter full underwriting, without seconda r without second fe (with or withou	limited underwritin ry gurarantee) ary gurarantee) it secondary gurara	Includes ssue, "short form a g, jet issue, "short intee)	app") form app")			
16.	Is the reporting entity licensed or chartered, register						Yes [ X ] No [	]
16.1	If no, does the reporting entity assume reinsurance domicile of the reporting entity?						Yes [ ] No [	]

# **FIVE-YEAR HISTORICAL DATA**

		1 2022	2 2021	3 2020	4 2019	5 2018
	Balance Sheet (Pages 2 and 3)					
1.	Total admitted assets (Page 2, Line 28)	134,118,899	43,856,118	18,517,844	2,681,552	2,334,561
2.	Total liabilities (Page 3, Line 24)	90,120,570	22,775,768	6,210,530	325 , 180	3,593
3.	Statutory minimum capital and surplus requirement	28,042,688	10,196,656	3,361,336	1,500,000	1,500,000
4.	Total capital and surplus (Page 3, Line 33)	43,998,329	21,080,350	12,307,314	2,356,372	2,330,968
	Income Statement (Page 4)					
5.	Total revenues (Line 8)	399,594,562	126,683,280	28,240,231	0	0
6.	Total medical and hospital expenses (Line 18)	342,460,302	113,773,299	23,663,615	0	(1,497)
7.	Claims adjustment expenses (Line 20)	7,832,640	2,387,991	586 , 151	0	0
8.	Total administrative expenses (Line 21)	41,036,215	12,260,317	2,870,780	1,680	10,228
9.	Net underwriting gain (loss) (Line 24)	1,732,310	(1,738,327)	1,119,685	(1,680)	(8,731)
10.	Net investment gain (loss) (Line 27)	1,648,582	31,995	36,278	33,825	15,993
11.	Total other income (Lines 28 plus 29)	0	0	0	0	0
12.	Net income or (loss) (Line 32)	1,770,344	(1,210,424)	943,562	27,461	5,737
	Cash Flow (Page 6)					
13.	Net cash from operations (Line 11)	41,896,859	7,222,834	5,341,015	15,276	8,621
	Risk-Based Capital Analysis					
14.	Total adjusted capital	43,998,329	21,080,350	12,307,314	2,356,372	2,330,968
15.	Authorized control level risk-based capital	14,021,344	5,098,324	1,680,668	10,698	7,161
	Enrollment (Exhibit 1)					
16.	Total members at end of period (Column 5, Line 7)	32,028	12,033	3,185		
17.	Total members months (Column 6, Line 7)	349,573	123,346	31,799		
	Operating Percentage (Page 4) (Item divided by Page 4, sum of Lines 2, 3 and 5) x 100.0					
18.	Premiums earned plus risk revenue (Line 2 plus Lines 3 and 5)	100.0	100.0	100.0	100.0	100.0
19.	Total hospital and medical plus other non-health (Lines 18 plus Line 19)					
20.	Cost containment expenses					0.0
21.	Other claims adjustment expenses					
22.	Total underwriting deductions (Line 23)					
23.	Total underwriting gain (loss) (Line 24)	0.4	(1.4)	4.0	0.0	0.0
	Unpaid Claims Analysis (U&I Exhibit, Part 2B)					
24.	Total claims incurred for prior years (Line 17, Col. 5)	9,538,298	2,567,010	0		0
25.	Estimated liability of unpaid claims-[prior year (Line 17, Col. 6)]	15,379,240	2,853,959	0		0
	Investments In Parent, Subsidiaries and Affiliates					
26.	Affiliated bonds (Sch. D Summary, Line 12, Col. 1)					
27.	Affiliated preferred stocks (Sch. D Summary, Line 18, Col. 1)		0	0	0	
28.	Affiliated common stocks (Sch. D Summary, Line 24, Col. 1)		0	0	0	
29.	Affiliated short-term investments (subtotal included in Schedule DA Verification, Col. 5, Line 10)		0			
30.	Affiliated mortgage loans on real estate					
31.	All other affiliated					
32.	Total of above Lines 26 to 31	0	0	0	0	0
33.	Total investment in parent included in Lines 26 to					

NOTE: If a party to a merger, have the two most recent years of this exhibit been restated due to a merger in compliance with the disclosure				
requirements of SSAP No. 3, Accounting Changes and Correction of Errors?	Yes [	] No	0 [	]
If no, please explain:				


# SCHEDULE T PREMIUMS AND OTHER CONSIDERATIONS

Allocated by States and Territories

Allocated by States and Territories  1 Direct Business Only												
	States at a		Active Status	2 Accident and Health	Medicare	4 Medicaid	5 CHIP Title	6 Federal Employees Health Benefits Program	7 Life and Annuity Premiums & Other	8 Property/ Casualty	9 Total Columns 2	10 Deposit-Type
1.	States, etc. Alabama	Λ1	(a) N	Premiums	Title XVIII	Title XIX	XXI	Premiums	Considerations	Premiums	Through 8	Contracts
2.	Alaska		N								0	
3.	Arizona	AZ	N								0	
4.	Arkansas		N								0	
5.	California	CA	N								0	
6.	Colorado	CO	N								0	
7.	Connecticut		N								0	
8.	Delaware	DE	N								0	
1	District of Columbia	DC	N								0	
10. 11.	FloridaGeorgia		N N								0	
	Hawaii	-	N								0	
	Idaho	ID	N								0	
14.	Illinois	IL	L		58 , 112 , 495						58 , 112 , 495	
15.	Indiana	IN	L		108,475,772						108,475,772	
16.	lowa		N								0	
17.	Kansas		N								0	
18.	Kentucky		N								0	
1	Louisiana Maine		N		······					·····	0	
20.	Maryland		N N						•••••		0	
	Massachusetts	MA	N								0	
	Michigan	MI	L		243,099,070						243,099,070	
	Minnesota		N								0	
25.	Mississippi	MS	N								0	
26.	Missouri	-	N								0	
	Montana		N								0	
1	Nebraska		N								0	
	New Hampshire		N N								0	
	New Jersey		N								0	
32.	New Mexico		N								0	
	New York		N								0	
34.	North Carolina	NC	N								0	
35.	North Dakota	ND	N								0	
36.	Ohio		N								0	
37.	Oklahoma	-	N								0	
38.	Oregon	OR	N								0	
	Pennsylvania		N N								0	
41.	South Carolina	SC	N								0	
42.	South Dakota	SD	N								0	
	Tennessee	TN	N								0	
44.	Texas	TX	N								0	
-	Utah	UT	N								0	
	Vermont		N								0	
1	Virginia		N								0	
	Washington		N								0	
	West Virginia Wisconsin		N N						•••••		0	
	Wyoming	WY	N								0	
52.	American Samoa		N								0	
53.	Guam	GU	N								0	
1	Puerto Rico		N								0	
1	U.S. Virgin Islands	VI	N								0	
56.	Northern Mariana	MD	N								0	
57.	Islands Canada	MP CAN	N N						•••••		0	
58.	Aggregate Other	OAN										
	Aliens		XXX	0	0	0	0	0	0	0	0	0
59. 60.	Subtotal Reporting Entity Contributions for Er	nployee		0	409,687,337	0	0	0	0	0	409,687,337	0
61	Benefit Plans		XXX		409,687,337	0		0	0	^	0	
61.	Totals (Direct Busine DETAILS OF WRITE		XXX	0	403,087,337	0	0	0	0	0	409,687,337	0
58001.	DETAILS OF WRITE		XXX		<u> </u>					<u> </u>		
58002.			XXX									
58003.			XXX									
	Summary of remainir write-ins for Line 58 for overflow page	from	XXX	0	0	0	0	0	0	0	0	0
58999.	Totals (Lines 58001 58003 plus 58998)(Labove)		XXX	0	0	0	0	0	0	0		0
	e Status Counts:		^^^	ı U	ı			. ,	. 0		<u> </u>	

/ - \ A - L' -	-			<u> </u>	
<ul><li>(a) Active</li></ul>		stati	ıs	COL	nts:
(4) / 101.10	_				

# SCHEDULE Y - INFORMATION CONCERNING ACTIVITIES OF INSURANCE MEMBERS OF A HOLDING COMPANY GROUP PART 1 - ORGANIZATIONAL CHART



This organizational chart reflects the insurance entity reporting system and identifies the relationship between the ultimate parent and all member insurers. The ultimate controlling company is a Fortune 7 company with numerous subsidiaries, the majority of which do not interact with the insurance entities.

(1) Insurers/HMO's

Double borders indicate entity has subsidiaries shown on the same page.


Bold borders indicate entity has subsidiaries shown on a separate page.

Percentages are rounded to the nearest whole percent and based on ownership of voting rights.


<sup>\*1</sup> Coram Clinical Trials, Inc. is also 25% owned by Aetna Life Insurance Company

# SCHEDULE Y - INFORMATION CONCERNING ACTIVITIES OF INSURANCE MEMBERS OF A HOLDING COMPANY GROUP

#### PART 1 - ORGANIZATIONAL CHART



<sup>\*1</sup> PHPSNE Parent Corporation is also 45% owned by third parties.
\*2 CVS Cabot Holdngs Inc. is also 99.72% owned by Coram Clinical Trials, Inc.
\*3 CVS Shaw Holdngs Inc. is also 99.72% owned by Coram Clinical Trials, Inc.
\*4 Omnicare, LLC is also owned by CVS Cabot Holdings Inc and CVS Shaw Holdngs Inc., each with 49.86% ownership.





<sup>\*1</sup> PT. Aetna Global Benefits Indonesia is also 20% owned by Suhatsyah Rivai, Aetna's Nominee.


\*2 Aetna Global Benefits (Middle East) LLC is also 51% is owned by Euro Gulf LLC, Aetna's Nominee.

\*3 Indian Health Organisation Private Limited is 0.019857% owned by Aetna Global Benefits (Asia Pacific) and 99.980143% owned by Aetna Global Benefits (Singapore) PTE. LTD.

\*4 Virtual Home Health Care L.L.C. is also 51% owned by CBD Commercial Brokers LLC, Aetna's Nominee








#### SCHEDULE Y - INFORMATION CONCERNING ACTIVITIES OF INSURANCE MEMBERS OF A HOLDING COMPANY GROUP

#### PART 1 - ORGANIZATIONAL CHART



<sup>\*1</sup> Aetna ACO Holdings Inc. is owned by Aetna Life Insurance Company (302 shares); Aetna Health Inc. (PA) (198 shares); and Aetna Health Holdings, LLC (1 share).


<sup>\*2</sup> Innovation Health Holdings, LLC is also 50% owned by Inova Health System Foundation.

<sup>\*3</sup> Texas Health + Aetna Health Insurance Holding Company LLC is also 50% owned by Texas Health Resources.
\*4 Banner Health and Aetna Health Insurance Holding Company LLC is also 50% owned by Banner Health.


<sup>\*5</sup> Allina Health and Aetna Insurance Holding Company LLC is also 50% owned by Allina Health.
\*6 Sutter Health and Aetna Insurance Holding Company LLC is also 50% owned by Sutter Health Plan Products Organization, LLC.

40.7

### ANNUAL STATEMENT FOR THE YEAR 2022 OF THE Aetna Health of Michigan Inc.



<sup>\*</sup> Aetna Capital Management, LLC owns 100% of the voting rights of Aetna Partners Diversified Fund, LLC ("APDF"). APDF is a fund of hedge funds and certain subsidiaries of CVS Health Group invest in this fund, which does not confer any managing or controlling ownership interests in APDF.



<sup>\*1</sup> Aetna ACO Holdings Inc. is owned by Aetna Life Insurance Company (302 shares); Aetna Health Inc. (PA) (198 shares); and Aetna Health Holdings, LLC (1 share).
\*2 Innovation Health Holdings, LLC is also 50% owned by Inova Health System Foundation.

<sup>\*3</sup> Texas Health + Aetna Health Insurance Holding Company LLC is also 50% owned by Texas Health Resources.

<sup>\*4</sup> Banner Health and Aetna Health Insurance Holding Company LLC is also 50% owned by Banner Health.

<sup>\*5</sup> Allina Health and Aetna Insurance Holding Company LLC is also 50% owned by Allina Health System.

<sup>\*6</sup> Sutter Health and Aetna Insurance Holding Company LLC is also 50% owned by Sutter Health Plan Products Organization, LLC.
\*7 Coram Clinical Trials, Inc. is also 75% owned by CVS Pharmacy, Inc.

<sup>\*8</sup> CVS Cabot Holdings Inc. is also .28% owned by Aetna Inc.

<sup>\*9</sup> CVS Shaw Holdings Inc. is also .28% owned by Aetna Inc.

<sup>\*10</sup> Remaining .28% owned by Aetna Inc. CVS Cabot Holdings Inc. and CVS Shaw Holdings Inc. each owning 49.86%.

# **OVERFLOW PAGE FOR WRITE-INS**

# NONE